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1 STABLE SUPPRESSION OF MUTANT KRAS IN C26
MURINE COLON CARCINOMA CELLS BY RNA
INTERFERENCE LEADS TO COMPLETE LOSS OF
METASTATIC POTENTIAL
Smakman N, Borel Rinkes I, Kranenburg O, Department of
Surgery (G04.228), University Medical Centre Utrecht, Utrecht,
The Netherlands
INTRODUCTION AND AIM: Mutational activation of the KRAS
proto-oncogene is an initiating event during the development of 45%
of human colorectal carcinomas (CRC). The aim of this study was to
assess whether mutant KRAS is essential during the late metastatic
stages of tumour growth when cells have acquired multiple additional
genetic changes. PATIENTS AND METHODS: RAS status of C26
murine CRC cells was assessed by RAS activity assays, RT-PCR and
cDNA sequencing. The mutant KRAS mRNA was targeted by RNA
interference using a lentivirus-based expression system. Knockdown
of mutant KRAS was tested by Western blotting. Cell morphology,
cell proliferation and cell cycle distribution were all tested with
standard assays. Liver metastases were induced by intrasplenic
injection of tumour cells in BALB/c mice. The formation of liver
metastases was analysed by bioluminescence imaging. RESULTS:
C26 cells harbour constitutively active KRAS due to an activating
mutation in codon 12. We isolated stable cell lines in which the
mutant KRAS allele was stably suppressed by RNA interference
(C26-KRKD). C26-KRKD cells showed reversion of morphological
transformation, exhibited a reduced proliferation rate, showed
restored contact inhibition and an increased percentage of cells in
G1. While mice challenged with control cells developed massive liver
metastases within 12 days, the potential to form liver metastasis was
completely abrogated in KRAS-suppressed cells. CONCLUSION:
Sequence-specific suppression of mutant KRAS by RNA inter-
ference in a highly aggressive and metastatic CRC cell line leads to
reversion of malignant characteristics in vitro and to complete abro-
gation of the metastatic potential in vivo.
2 RE-HEPATECTOMIES IN COLORECTAL
METASTASES (CRM)
Sa´nchez Claria´ R, de Santiban˜es E, Palavecino M, Pekolj J,
Hepato-Pancreato-Biliary Surgery and Liver Transplantation,
Hospital Italiano, Buenos Aires, Argentina
INTRODUCTION AND AIM: Surgical resection is the only
potentially curative treatment in liver metastases from colorectal
cancer. 70–80% of these patients will present recurrence in the first 5
years. From this percentage, 50–60% will recur only in liver and only
15% will be resectable. The aim of this study is to analyse our results
in patients re-resected with curative intention and to determine
factors that influence the survival rate of this group of patients.
PATIENTS AND METHODS: 705 hepatectomies for the treat-
ment of CRM were performed. A re-hepatectomy was carried out in
75 patients. A second re-hepatectomy was made in 5 patients while a
third re-hepatectomy was needed in one patient. Mean age was 59
years old (range 29–73) and mean follow-up was 27 months (range
9–80). RESULTS: 53 major hepatectomies and 28 wedge resections
were performed. The most frequent site of recurrente was the liver.
Mortality was 0% and morbidity was 21%. Global and disease-free
survival were 31% and 27%, respectively, at 5 years. Variables that
influenced the survival rate were anatomical resections and post-
operative chemotherapy. CONCLUSION: Hepatic recurrences
after surgical treatment can be re-resected with a minimum risk. The
survival rate, motality, morbidity and recurrence pattern were similar
to the first resection. The absence of alternative treatments deter-
mines an agressive surgical approach of these patients.
3 SIMULTANEOUS COLORECTAL AND HEPATIC
RESECTION FOR COLORECTAL CANCER: SHORT- AND
LONG-TERM OUTCOMES
Ferna´ndez D1, de Santiban˜es E1, Vaccaro C2, Bonadeo F2, Sa´nchez
Claria´ R1, Pekolj J1, (1) Hepato-Pancreato-Biliary Surgery and Liver
Transplantation; (2) General Surgery, Hospital Italiano, Buenos
Aires, Argentina
INTRODUCTION AND AIM: The aim of this study is to analyse
the results of simultaneous colorectal cancer and liver metastases
resection for colorectal cancer. PATIENTS AND METHODS:
Between June 1982 and February 2003, 750 patients underwent liver
resection for colorectal metastases. Liver resection was performed
simultaneously with a colorectal resection in 137 cases, representing
the population of this study. Mortality rate, morbidity rate, overall
and disease-free survival times were analysed. Median follow-up was
30 months (range: 11–162). Prognostic factors and their influence on
outcomes were analysed. RESULTS: Median hospital stay was 8
days (range: 4–24). Morbidity rate was 21%, including 18 cases of
pleural effusion, 14 cases of wound abscesses, 8 hepatic failures, 3
systemic infections, 3 abdominal abscesses and 1 colonic anasto-
motic leakage. Operative mortality rate was 2.1%. Recurrence rate
was 64%. Overall and disease-free survival at 1, 3 and 5 years were
91%, 39% and 24%, and 69%, 34% and 21%, respectively. Prog-
nostic factors with notable influence on patient outcomes were nodal
stage, number of liver metastases, diameter (smaller or larger
than 5 cm) and CEA level more than 20 ng/ds. CONCLUSION:
Simultaneous resection of colorectal cancer and liver metastases can
be performed with low morbidity and mortality rates, thus avoiding a
second surgical procedure.
4 INFLAMMATORY CYTOKINE INDUCTION
FOLLOWING HEPATIC CRYOTHERAPY,
RADIOFREQUENCY ABLATION, MICROWAVE TISSUE
ABLATION AND STANDARD HEPATIC RESECTION
Ahmad F1, Strickland A1, Basit R1, Beckingham I2, Lloyd D1,
(1) Department of Hepatobiliary Surgery, Leicester Royal
Infirmary, Leicester, UK; (2) Department of Surgery, Queens
Medical Centre, Nottingham, UK
INTRODUCTION AND AIM: Background: Hepatic cryoablation
has been complicated by “cryoshock”, a variant of the systemic
inflammatory response syndrome (SIRS). Pro-inflammatory cyto-
kines TNF-a, IL-1b and IL-6, and anti-inflammatory cytokines
such as IL-10 have been implicated as important mediators of
this response. PATIENTS AND METHODS: Following laparo-
tomy, adult rats underwent cryoablation, radiofrequency ablation
(RFA), microwave tissue ablation (MTA) or resection of 15%, 33%
or 66% of the total liver volume. Blood samples were taken pre-
operatively, and at 1, 3, 6, 24 and 48 hours post-procedure. The
levels of TNF-a, IL-1b, IL-6 and IL-10 were measured using stan-
dard enzyme-linked immunosorbent assay techniques. RESULTS:
Following 15% and 33% ablation or resection, all animals tolerated
the procedures well. All animals undergoing 66% hepatic resection or
MTA survived to 48 hours. However, there was a 100% mortality
rate at 6 hours following 66% cryoablation and 66% RFA. No
significant difference in cytokine levels was observed in any group
following 15% ablation or resection, compared to controls. Follow-
ing 33% resection or ablation using MTA and RFA, cytokine levels
peaked at 6 hours and dropped within 24 hours. Significantly raised
IL-6, IL-1b and IL-10 levels were noted in the 33% and 66%
cryoablation groups, the 66% RFA group and the 66% resection
group. These elevated cytokine levels remained high for at least
24 hours. The 66% MTA group did not show a similar cytokine
response. CONCLUSION: Large volume hepatic ablation using
cryotherapy and RFA results in a significant inflammatory cytokine
response and high mortality. MTA, however, does not induce a
similar cytokine response, and was less than that observed following
surgical resection.
5 TREATMENT WITH RADIOACTIVE RESIN
MICROSPHERES IN A LIVERMETASTATIC EXPERIMENTAL
MODEL IN RATS—IS IT EFFECTIVE?
Morioka CY3, Tazawa K1, Arai H1, Pereira_Filho DS2,
Matheus AS3, (1) 2nd Depart of Surgery, Toyama Medical
and Pharmaceutical University, Toyama, Japan; (2) Depart of
Clinical Surgery, Federal University of Vale do Rio Sa˜o Francisco,
Vale do Rio Sa˜o, Francisco; (3) Department of Surgery, University
of Sao Paulo, Sa˜o Paulo, Brazil
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INTRODUCTION AND AIM: Radiotherapy has been used in the
treatment of many malignancies. However, there has been little
success in controlling established liver metastases. In cases of liver
metastases from colon cancer, prophylactic therapy after tumoral
resection appears appropriate to prevent the metastatic foci. There-
fore, we have developed an experimental model of intrahepatic
metastasis and studied the effectiveness of radiolabelled micro-
spheres. The purpose of this study was to verify the uptake of 32P-
labelled resin microspheres (LRM) in rats. PATIENTS AND
METHODS: AH60C: a hepatoma cell line derived from ascites
hepatoma cell line and Donryu rats was used for these experiments.
Tumor cell suspensions were inoculated intraportally. Animals were
divided in 5 groups: Group A received no treatment (positive control,
n=35), Group B received LRM 4 days before inoculation (n=42),
Group C received LRM at same time of tumor inoculation (n=38),
Group D received LRM 4 days after tumor inoculation (n=12), and
Group E received only LRM (n=11). At day 4 and day 48 after the
injection, 4 intraportally injected animals were radiographed to study
the organ distribution of microspheres. Animals were followed up.
Survival time was studied up to 60 days. Necropsy was performed
after death and specimens were sent for histopathological analysis.
RESULTS: The distribution of the microspheres within the liver
using the portal vein inoculation method was homogeneous.
Percentage distribution of radioactivity in tissue 4 days after injection
showed 81.6% in the liver, 0.11% in the leg, 0.02% in the lung,
0.01% in the spleen, and 0.04% in the kidney. These levels were
maintained in the animals at day 48 after the microspheres injection.
Therefore, it showed the highest uptake in liver when compared with
other organs. Survival rates after 60 days were 2.9%, 40%, 23.8%,
0%, and 0% in Groups A, B, C, D, and E, respectivelly.
CONCLUSION: This study suggests that radioactive resin micro-
spheres treatment was shown to be effective as prophylactic treat-
ment of intrahepatic metastases. However, further studies will be
necessary to clarify the mechanisms.
6 SYNERGISTIC EFFECT OF INTERSTITIAL LASER
COAGULATION AND DOXORUBICIN IN A MURINE MODEL
FOR SOLITARY COLORECTAL LIVER METASTASIS
Veenendaal LM, van Hillegersberg R, Smakman N, van der Bilt J,
Kranenburg O, Borel Rinkes I, Department of Surgery, University
Medical Center Utrecht, Utrecht, The Netherlands
INTRODUCTION AND AIM: Interstitial laser coagulation (ILC)
is gaining acceptance for treatment of irresectable colorectal liver
metastases. However, local recurrence rates are still high. To over-
come this problem we investigated the potential of adjuvant systemic
therapy after ILC in a murine model. PATIENTS AND METH-
ODS: Liver metastases were established by subcapsular implantation
of C26-luciferase coloncarcinoma fragments (1r1 mm) in the liver
of 32 BALB/c mice. Animals were randomly allocated to one of four
treatments groups (n=8 per group): (A) sham treatment, (B) 1 mg/
kg doxorubicin injections, (C) ILC (Nd:YAG, 6 W/cm, 400 J), (D)
ILC (Nd:YAG, 6 W/cm, 400 J) followed by 1 mg/kg doxorubicin
injections. At different time points tumor load was measured by non-
invasive in vivo bioluminescent imaging. At day 28 mice were sacri-
ficed and immunohistochemistry was performed with HE and
NADH (marker of mitochondrial viability) staining. RESULTS:
Groups A and B demonstrated an exponential increase in tumor load.
Mice treated with ILC showed an initial decrease of tumor size,
followed by recurrent tumor growth after 5 days in 7/8 mice (88%).
This was confirmed by HE and NADH staining. The group treated
with combined ablation and doxorubicin demonstrated no recur-
rence at all (8/8 mice). CONCLUSION: We were able to establish a
murine model for solitary liver metastases in which recurrent tumor
arises after ILC treatment. Combination of interstitial laser coagu-
lation and doxorubicin had a strong synergistic effect leading to
complete remission. These results provide a solid base for further
investigation of combined treatment of chemotherapy and ILC for
colorectal metastases.
7 ISCHEMIA/REPERFUSION ACCELERATES THE
OUTGROWTH OF HEPATIC MICROMETASTASES IN A
HIGHLY STANDARDIZED MURINE MODEL
van der Bilt JDW1, te Velde EAV1, Nijkamp MW1, Smakman N1,
Veenendaal LM1, Voest EE2, van Diest PJ3, Kranenburg O1, van
Hillegersberg R1, Borel Rinkes IHM1, (1) Department of Surgery;
(2) Department of Medical Oncolog; (3) Department of Pathology,
University Medical Center Utrecht, Utrecht, The Netherlands
INTRODUCTION AND AIM: During liver surgery for colorectal
liver metastases, ischemia/reperfusion (I/R) often occurs due to
hemorrhage or vascular clamping. Whereas the adverse effects of I/R
on hepatocellular injury are well documented, the influence of I/R on
the outgrowth of residual micrometastases is unknown. The aim of
our study was to investigate the effects of hepatic I/R on the
outgrowth of pre-established colorectal micrometastases in a highly
standardized murine model and to evaluate the putative protective
effect of alternative clamping methods. PATIENTS AND METH-
ODS: Five days following intrasplenic injection with C26 colon
carcinoma cells the vascular structures to the left lobe were clamped
under hemodynamically stable conditions. Markers of oxidative
stress, hepatocellular damage and tumor growth were assessed over
time. Next, we analyzed the effect of ischemic preconditioning,
intermittent clamping and portal clamping on hepatocellular damage
and tumor growth. RESULTS: The outgrowth of micrometastases in
occluded liver lobes was accelerated 5–6-fold compared with non-
occluded lobes and was associated with the presence of hepatocel-
lular necrosis 4–7 days following I/R. Accelerated tumor growth and
necrosis could be completely prevented by occluding blood flow
intermittently or by portal clamping. In contrast, ischemic precon-
ditioning failed to protect against hepatocellular necrosis and tumor
growth, although early hepatocellular damage was largely prevented
by all methods. CONCLUSION: Our results identify I/R as a strong
stimulus of recurrent intrahepatic tumor growth and indicate that
protection against I/R-induced tissue necrosis cross-protects against
this phenomenon.
8 POSITRON EMISSION TOMOGRAPHY AS VALUABLE
TEST BEFORE SURGERY FOR SUSPECTED COLORECTAL
CANCER LIVER METASTASES
Gutierrez G, Villar J, Ramia JM, Muffak K, Garrote D, General
Surgery, Hospital Virgen de las Nieves, Granada, Spain
INTRODUCTION AND AIM: Positron emission tomography
(PET) is a diagnostic tool to detect temporal tissue using a radio-
isotope (fluoro-2-deoxi) added to glucose. We present our experience
using this technique for colorectal liver metastasis (CRLM).
PATIENTS AND METHODS: Since January 2002 our hospital has
incorporated use of PET. One of the indications is the patient with
suspected CRLM from other imaging techniques (echography, CT)
and/or elevation of CEA. For 2 years we have evaluated 32 patients, 4
synchronic lesions and 28 metachronic. We evaluated the change in
the therapeutic strategy after PET, and the specificity (Sp), sensitivity
(S), and predictive positive and negative values (PPV NPV).
RESULTS: Metastasis was confirmed in 27 patients. For hepatic
extension: S 92.6%, Sp 100%, PPV 100%, NPV 71%; extrahepatic
disease: S 69%, Sp 94.7%, PPV 90%, NPV 81.8%. 46.7% of total
liver lesions were not detected with PET. 37.5% of PET results led to
a change in the management of the disease. Five laparotomies were
avoided. In 17 of 21 operations a R0 resection was accomplished.
CONCLUSION: PET is a high profitable test for suspicion of
CRLM because of its important capacity to detect intrahepatic
disease. The results modified the therapeutic strategy, decreasing
from 34% to 19% the laparotomies in which a R0 resection was not
possible.
9 COMPLICATIONS AND EFFECTIVENESS OF
LASER-INDUCED THERMOTHERAPY OF LIVER
METASTASES VIA PERCUTANEOUS AND OPEN ACCESS
Ritz JP1, Lehmann K1, Frericks B2, Reissfelder C1, Roggan A3,
Buhr H1, (1) Department of General Surgery; (2) Department of
Radiology; (3) Department of Lasermedicine, Charite Campus
Benjamin Franklin, Berlin, Germany
INTRODUCTION AND AIM: Treating liver tumors by ablation
procedures like laser-induced thermotherapy (LITT) has gained
wide acceptance. Ablation procedures can be used percutaneously
and via laparotomy. It remains unclear which is the best access for
this therapy. The aim of this study was to compare the results of
percutaneous and open LITT. PATIENTS AND METHODS:
Patients with inoperable liver metastases were included in the study.
Exclusion criteria: extrahepatic tumor, 45 metastases; diameter
45 cm. LITT was performed percutaneously with open MRI [group
I]. LITT was done via laparotomy under US monitoring [group II].
Abdominal tumor staging was performed here. Energy per metastasis
(J/MVol) and effectiveness of the procedure (LVol/10 kJ) was
calculated. Follow-up was done 24 h after the intervention and every
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3 months. RESULTS: 103 patients (55 men, 48 women; aged 45–86
years) with 227 liver metastases were included in the study. 58
patients were assigned to group I, 45 patients to group II. 14 cases in
group II had additional tumor manifestations (liver metastases n=7,
peritoneal carcinoma: n=3, LN involvement n=3, extrahepatic
tumor n=1), which led to exclusion from therapy in 10 cases.
Complications: pleural effusion (n=9), subcapsular hematoma
(n=4), biliary fistula (n=2), liver abscess (n=2), wound infection
(n=2), pneumonia (n=1). There were no therapy-related deaths.
Two patients each in group I and group II had an intralesional
recurrence during follow-up (3–48 months). CONCLUSION:
(1) Percutaneous and open laser-induced thermotherapy leads to
complete destruction of liver metastases with a diameter of up to
5 cm. (2) The percutaneous approach is associated with a lower
complication rate and shorter hospital stays than the open approach.
(3) The open approach is more effective with regard to the inducible
lesion volume than the percutaneous approach and it facilitates the
detection of additional prognostically relevant tumor manifestations
that would have been missed by the percutaneous approach.
10 RESULTS OF SURGICAL CARE FOR LIVER
METASTASES OF CRC ORIGIN IN PATIENTS OVER THE
AGE OF 70 YEARS
Lang IB, Jakab F, General and Vascular Surgery, Uzsoki University
Hospital, Budapest, Hungary
INTRODUCTION AND AIM: Surgical resection is accepted as
basic evidence in curative management of liver metastases of CRC
origin. The older generation over 70 years of age is underrepresented
in the literature with regard to curative liver resections and onco-
logical treatment. Aims of novel concepts of aggressive operative
therapy, downstaging via of neoadjuvant chemotherapy and long-
term follow-up also apply to a special group of the patients above age
of 70. PATIENTS AND METHODS: The liver registry shows 410
cases of liver metastases of CRC origin at our department, among
them 44 patients over the age of 70 years. Patient selection for surgery
was based upon Karnofsky index, aspects of anesthesia, and esti-
mation of reserve liver capacity. Two groups of patients with liver
secondaries were compared under and over the age of 70 years by
means of statistical analysis. RESULTS: Major complications were
listed as bleeding, bile collection or abscess formation and pneu-
monia. The complication rate in the elderly group was 21% vs 17%
(ns). Mortality rate was 3.1% vs 3.5% (ns). No significant difference
showed in OA 5-year survival rate (39% vs 40%, ns). CONCLU-
SION: The ever-improving results of segmental hepatectomies and
repeat surgical interventions supported with the modality of neoad-
juvant chemotherapy suggest that more elderly patients could benefit
from surgical resection. Our comprehensive analysis proves that age
by itself is not a predictive value of worse outcome of metastatic liver
surgery for a carefully selected cohort of patients over the age of 70.
11 A RATIONAL BASIS FOR TIMING OF FOLLOW-UP CT
SCANS FOLLOWING HEPATECTOMY (HPX) FOR
COLORECTAL LIVER METASTASES (CLM)
Glendenning J1, Poston GJ2, Nesbitt C1, Byrne C2, Ghaneh P1,
(1) Surgery, University of Liverpool, Liverpool UK; (2) Surgery,
University Hospital Aintree, Liverpool, UK
INTRODUCTION AND AIM: HPX is the only treatment for CLM
that offers curative intent.460% of cases recur after HPX for CLM,
and increasingly patients undergo repeat HPX. Uncertainty persists
regarding the timing of follow-up CT scans after first HPX. Follow-
up scans are expensive, add psychological morbidity and involve
considerable radiation exposure.Such scans are only of benefit if
detecting potentially treatable CLM recurrence. This study evaluates
timing of detection of post-HPX liver-only CLM recurrence to
determine a practical follow-up protocol. PATIENTS AND
METHODS: A prospectively collected single-centre data set was
examined. 5-year follow-up data identified 184 CLM patients
undergoing HPX. Results were stratified for survival, timing and site
of recurrence, repeat-HPX with curative intent. RESULTS: 1 liver-
only recurrence (LOR) 53 months post-HPX, 4 extrahepatic
recurrences (EHR); no repeat-HPX. 4–6 months: 21 LOR
(14 unilateral); 10 HER, 1 repeat-HPX. 7–9 months: 13 LOR
(7 unilateral); 5 HER; 3 repeat HPX. 10–12 months: 10 LOR (7
unilobar); 11 HER; 3 repeat HPX. 13–18 months: 6 LOR (3
unilobar); 3 HER; 2 repeat-HPX. 19–24 months: 5 LOR (3 unilo-
bar); 2 HER; 2 repeat HPX. 25–60 months: 8 LOR (5 unilobar); 9
HER; 3 repeat-HPX. CONCLUSION: Very few cases recurring56
months post-HPX were amenable to repeat HPX. Peak CLM
recurrences amenable to repeat HPX occur between 7 and 24
months post-HPX. Therefore a reasonable follow-up CT protocol
would be 6, 12, 24, 36 and 48 months post-HPX.
12 DOES TRANSARTERIAL CHEMOEMBOLIZATION
IMPROVE SURVIVAL IN PATIENTS WITH COLORECTAL
LIVER METASTASES TREATED BY PERCUTANEOUS
RADIOFREQUENCY THERMAL ABLATION?
Zadrozny D1, Sledzinski Z1, Studniarek M2, Adamonis W1,
Zbrzezniak G2, Stefaniak T1, Gorycki T2, Nowakowski M2,
(1) Department of General and Endocrine Surgery and
Transplantology; (2) Department of Radiology, Medical University
of Gdansk, Poland, Gdansk, Poland
INTRODUCTION AND AIM: Transarterial chemoembolization
(TACE) is a widely used method for palliative locoregional treatment
of colorectal liver metastases. Percutaneous radiofrequency thermal
ablation (PRFTA) is a method for local control of cancer foci. The
aim of this study was to compare results of PRFTA with and without
previous TACE in the treatment of inoperable colorectal liver
metastases. PATIENTS AND METHODS: Between April 2001
and April 2004, 144 patients with colorectal liver metastases were
treated using PRFTA. In 23 cases radiofrequency was combined with
TACE. The indication for chemoembolization was large tumour size
(over 5 cm). As a chemotherapeutic agent in all cases, 5-FU and
Spongostan (R) as the embolization material was used. PRFTA was
performed at least 6 days after TACE. RESULTS: No serious
adverse effects due to TACE were found, except the post-emboli-
zation syndrome; with pain as a main symptom. Due to pain the
PRFTA session could not be performed before the 4th to 6th post-
embolization day in 11 patients. The observed difference during
PRFTA was larger ablation zone with a more spherical character.
The computed median survival time after PRFTA due to colorectal
liver metastases in our material was 17 months. In the group treated
with combined TACE+PRFTA it was 32.6 months. The difference
is statistically significant ( p50.04). CONCLUSION: Our results
suggest that TACE combined with PRFTA may prolong survival in
patients with large inoperable colorectal liver metastases. This
observation should be confirmed in larger studies.
13 APPROPRIATENESS OF TREATMENT STRATEGIES
FOR COLORECTAL LIVER METASTASES (CLM): A
DECISION MODEL BASED ON CONSENSUS DETECTION
WITHIN AN INTERNATIONAL EXPERT PANEL
Poston GJ15, Nordlinger B1, Adam R2, Ruers T3, Primrose J4,
Figueras J5, Mentha G6, Roh M7, Curly S8, Vauthey N8, Rougier P9,
Alberts10, Schmoll HJ11, Patt Y12, Kunstlinger F13, Haller D14,
(1) Surgery, Hopital Ambroise Pare, Paris, France; (2) Surgery,
Hopital Paul Brousse, Paris, France; (3) Surgery, University of
Nijmegen, The Netherlands; (4) Surgery, University of
Southampton, UK; (5) Surgery, Cuitat Sanitaria de Bellvitge,
Barcelona, Spain; (6) Surgery, Hopital Cantonal, Geneva,
Swittzerland; (7) Surgery, Allegheny General Hospital; Pittsburgh,
USA; (8) Surgery, MD Anderson Cancer Center, Houston, USA;
(9) Gastroenterology, Hopital Ambroise Pare, Paris, France;
(10) Oncology, Mayo Clinic, Rochester, USA; (11) Oncology,
University Hospital of Halle, Germany; (12) Oncology, University of
Maryland, USA; (13) Radiology, Hopital Paul Brousse, Paris,
France; (14) Oncology, University Hospital of Pennsylvania, USA
INTRODUCTION AND AIM: CLM management is multi-
disciplinary; surgery is the only curative treatment but only possible
for 520% patients. Chemotherapy may render an additional 10–
20% resectable, but no consensus on treatment strategies exists.
PATIENTS AND METHODS: Following a comprehensive litera-
ture review, an international expert panel rated appropriateness of
resection, RFA, chemotherapy and their combination studying 1500
virtual CLM cases with the RAND-UCLA Appropriateness Model.
RESULTS: Overall agreement: 93.4–99.1%. Absolute resection
contraindications: non-resectable extrahepatic disease; surgically
unfit; disease involved 470%/46 segments liver. Characteristics
that influenced pre-operative chemotherapy: inadequate radiological
margins (67%); portal lymphadenopathy (89%); 2–4 metastases
(80%); 44 metastases (85%); largest metastasis 44 cm (85%);
bilobar metastases (70%); resectable extrahepatic disease (89%); R1
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resection (89%). CONCLUSION: A high level of agreement on
treatment strategy was detected with the international expert panel.
These strategies now translated into an interactive CD-ROM deci-
sion model to aid clinicians in day-to-day management of CLM.
14 REPEAT HEPATIC RESECTION: THE PROCEDURE
OF CHOICE FOR RECURRENT COLORECTAL
LIVER METASTASES
Shaw IM, Rees M1, John T, Hepatobiliary Unit, North Hampshire
Hospital, Basingstoke, UK
INTRODUCTION AND AIM: The management of patients with
recurrent colorectal liver metastases (RCLM) remains controversial.
Repeated liver resection presents a technical challenge and may be
associated with excess morbidity, and it has been suggested that
ablative techniques may be preferable. This study evaluates the role
of repeat liver resection for RCLM with specific reference to post-
operative morbidity and long-term survival. PATIENTS AND
METHODS: One thousand consecutive liver resections performed
between 1987 and 2004 are the subject of this prospective study,
including 800 resections performed in patients with colorectal liver
metastases. Of these, repeat hepatic resection for RCLM was
performed on 57 occasions in 52 patients (Group A), and the
outcomes were compared with those of the primary liver resection in
691 patients (Group B). RESULTS: There were no postoperative
deaths following repeat hepatic resection for RCLM compared with
1.9% postoperative mortality in Group B. Major postoperative
morbidity and median blood loss were similar in both groups (14% vs
25% and 400 ml vs 368 ml, respectively). Superior 1-, 3- and 5-year
survival rates were observed following repeat hepatic resection for
RCLM compared with Group B. 5-year survival following repeat
hepatectomy was 45%. CONCLUSION: The beneficial outcomes
observed following repeat liver resection(s) in selected patients with
RCLM confirm the experience of others. We urge caution in aban-
donment of surgery for unproven alternatives.
15 IS LONG-TERM SURVIVAL ACHIEVABLE AFTER
LIVER RESECTION FOR COLORECTAL METASTASES?
Burns AC2, Slavin J1, Wu A2, (1) Department of General Surgery,
Leighton Hospital, Crewe, UK; (2) Department of HPB Surgery,
University Hospital Aintree, Liverpool, UK
INTRODUCTION AND AIM: Liver resection for colorectal
metastases offers survival benefits although no randomised trial has
ever been done. PATIENTS AND METHODS: We have analysed
our data, collected prospectively, over a 12-year period. Operations
were performed as open procedures, although during the last year
10% were performed laparoscopically. RESULTS: Between 1990
and 2003, 280 patients (full data on 266: 176 male, 90 female,
median age 63 years, range 39–81) underwent resection of colorectal
liver metastases. Solitary metastases were resected in 109 patients
(41%). 185 patients had resections for bilobar disease (70%), 191
operations (71%) were major resections, and 22 patients underwent a
second liver resection for localised recurrent disease. Blood trans-
fusion was required in only 5%. Postoperative complications were
recorded in 49 patients (18%) including hepatic dysfunction (8%)
and pulmonary infection (0.5%), but only 11% of these were
discharged beyond the mean hospital stay of 14.6 days. There were
14 deaths (5%) mostly due to hepatorenal syndrome leading to
multi-organ failure. Median survival time with involvement of the
resection margin (26 patients) is 715 days (2 years), but when
uninvolved (206 patients) this increases to 1138 days (3.1 years). The
3-, 5- and 10-year survival rates are 50%, 30% and 11%, respectively.
The median survival for Dukes B (3 years) is 102 days longer than
those with Dukes C. CONCLUSION: Liver resection for colorectal
metastases can be performed with low morbidity and mortality in
appropriately selected patients. In a small number of patients long-
term survival may be achieved.
16 OXALIPLATIN/5-FU IN PATIENTS WITH
UNRESECTABLE LIVER COLORECTAL METASTASES
Dighe SS, Glantzounis G, Hewes J, Davidson B, (1) Hepato-
Pancreato-Biliary Surgery, Royal Free Hospital, London, UK
INTRODUCTION AND AIM: Although there is evidence
about the beneficial effect of oxaliplatin/5-FU as a downstaging
chemotherapy in patients with unresectable liver colorectal metas-
tases, few data are available about its effect in patients with resectable
disease. The aim of the present study was to look at the effect of
oxaliplatin/5FU on tumour size of resectable liver metastases.
PATIENTS AND METHODS: Between 01/2000 and 07/2004, 27
of a total 109 patients referred to our unit with potentially resectable
colorectal metastases underwent chemotherapy with oxaliplatin/
5-FU (median: 6 cycles). Number and size of metastases were eval-
uated from the pre- and post-chemotherapy radiology reports (CT
abdomen) and from histopathology reports. RESULTS: All patients
underwent liver resection. There were 49 metastases in 27 patients
pre-chemotherapy, with mean size 33.3+24.7 mm. Post-chemo-
therapy number of metastases was 52 and the mean size was
31.4+24.1 mm. 16 metastases increased in size, 21 reduced and 12
remained unchanged. The mean interval between date of referral and
surgery was 162 days, while the mean interval between last dose of
chemotherapy and surgery was 70 days. Histopathology showed
the presence of 55 metastases with mean size 34.9+26.3 mm.
CONCLUSION: Our results show that neo-adjuvant chemotherapy
with oxaliplatin/5-FU had no significant effect on tumour growth and
at the same time delayed the time to operation. Its use in patients with
resectable colorectal liver metastases should be evaluated further in
prospective randomised trials before its routine application.
17 PROGNOSTIC FACTORS AFTER SECOND
HEPATECTOMY FOR RECURRENT COLORECTAL
LIVER METASTASES
Thelen A1, Jonas S1, Benckert C1, Rudolph B2, Lopez-Ha¨ninnen E3,
Neuhaus P1, (1) Department of General, Visceral and Transplant
Surgery; (2) Department of Pathology; (3) Department of Radiology,
Charite-University Medicine, Berlin, Germany
INTRODUCTION AND AIM: Surgical resection is presently the
only approach that offers patients with liver metastases from colo-
rectal carcinoma a substantial chance of cure. Also, in the case of
recurrent metastases in the remaining liver the prognosis can be
improved by a second hepatectomy. The aim of this study was to
evaluate prognostic factors after second hepatectomy for recurrent
colorectal liver metastases. PATIENTS AND METHODS:
Between January 1988 and August 2004, 648 hepatectomies in 639
patients were performed, of which 72 resections were second hepa-
tectomies. The results of these patients were analyzed and prognostic
factors were evaluated. RESULTS: The 1- and 5-year survival in this
series was 86% and 49%, respectively. The 1- and 5-year disease-free
survival was 76% and 34%, respectively. A formally curative resec-
tion was the most important factor for prognostic benefit. Patients
with small metastases (diameter 550 mm) showed a survival
significantly superior to patients with larger lesions. Both grading and
the number of metastases had influence on survival in these patients,
but did not reach significance. Interestingly, the time between first
and second hepatectomy had no prognostic influence. CONCLU-
SION: The formally curative resection is the most important prog-
nostic factor after second hepatectomy for recurrent colorectal liver
metastases. Tumor-specific parameters also showed influence on the
prognosis in these patients. The distance between first hepatectomy
and the recurrence of hepatic metastases did not influence the
survival after resection.
18 DOES HEPATIC MICROWAVE TISSUE ABLATION
RESULT IN A SYSTEMIC INFLAMMATORY RESPONSE? AN
INVESTIGATION WITH A NOVEL MICROWAVE SYSTEM
Ahmad F, Strickland A, Basit R, Lloyd D, Department of
Hepatobiliary Surgery, Leicester Royal Infirmary, Leicester, UK
INTRODUCTION AND AIM: Hepatic cryoablation has been
complicated by cryoshock, a variant of the systemic inflammatory
response syndrome (SIRS). This study examined the SIRS response
to microwave tissue ablation (MTA) by assessing systemic and
organ-specific markers of inflammation. PATIENTS AND
METHODS: Following laparotomy, adult rats underwent ablation
or resection of 15%, 33% or 66% of the total liver volume. Control
rats underwent a sham laparotomy. Blood samples were taken pre-
operatively, and at 1, 3, 6, 24 and 48 hours post-procedure. Levels of
the pro-inflammatory cytokines TNF-a, IL-1b and IL-6 and anti-
inflammatory cytokine IL-10 were measured using standard ELISA
techniques. At 48 hours, animals were culled and one lung was
removed to assess the wet/dry lung ratio. Bronchoalveolar lavage
(BAL) was performed to quantify protein content and presence of
neutrophils in pulmonary oedema fluid as indicators of acute lung
injury. Urine was collected to assess the presence of retinol binding
protein (RBP), a urinary marker of renal damage. Lung, liver and
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kidney sections were examined using routine histological techniques.
RESULTS: All animals survived to 48 hours. No significant eleva-
tion in inflammatory cytokines was observed following any of the
MTA treatments, compared to controls. Protein content in BAL
fluid was not elevated. There was no significant difference in the wet/
dry lung ratio, compared to controls. Urinary RBP was also not
significantly raised. There was no histological evidence of acute
inflammation in the lungs or kidneys following any of the MTA
treatments. CONCLUSION: Systemic and organ-specific markers
of inflammation indicate that MTA does not result in a SIRS-type
response, even at large volumes of ablation.
19 IS A 3-MONTH POSTOPERATIVE CT SCAN AFTER
LIVER RESECTION FOR COLORECTAL SECONDARIES
WORTHWHILE?
Mitchell J1, Lobo DN2, Dowson CC1, Beckingham IJ1, (1) Section of
Surgery, University Hospital, Queen’s Medical Centre, Nottingham,
UK; (2) University Hospital Nottingham, Section of Surgery,
Nottingham, UK
INTRODUCTION AND AIM: It is our practice to perform tho-
racoabdominal CT scans on patients 3 months after undergoing
liver resection, mainly to document liver regeneration and to obtain a
baseline scan of the regenerated liver. The purpose of this audit was
to determine whether the 3-month postoperative CT scan had a
bearing on the management of patients with colorectal hepatic
metastases. PATIENTS AND METHODS: A retrospective audit
was performed on 89 patients who underwent liver resection for
colorectal secondaries. All patients had preoperative tho-
racoabdominal CT scans and intraoperative ultrasound scans. The
3-month postoperative CT scans were reviewed, mainly to look for
recurrent disease. RESULTS: Recurrent disease was found in 14
(17%) patients on the 3-month postoperative CT scan. Six patients
had liver metastases, 1 liver and lung metastases, 1 liver and bone
metastases, 5 lung metastases and 1 had omental metastases. Two of
the patients with recurrent liver metastases underwent a second
resection and one underwent treatment with radiofrequency
ablation. Of the remaining 11 patients, 9 were with treated with
chemotherapy and 2 received no further active treatment. The CT
scans showed evidence of liver regeneration in the remaining 75
patients. Artefacts were noted from the metal clips used at the time of
surgery and these scans formed the basis for comparison with future
scans. CONCLUSION: Recurrent disease was found in one of every
6.4 patients scanned 3 months after liver resection for colorectal liver
secondaries. Management was affected in the majority of patients
with positive scans and therefore, a 3-month postoperative CT scan is
worthwhile in patients undergoing liver resection for colorectal
secondaries.
20 IS PRINGLE MANOEVRE ROUTINELY NECESSARY
IN LIVER SURGERY?
Pistorius GA, Richter S, Lindemann W, Schilling MK, Clinic of
General, Visceral, Vascular and Pediatric Surgery, Homburg/Saar,
Germany
INTRODUCTION AND AIM: Since its first description the Pringle
manoevre has been used to reduce blood loss in hepatic surgery.
However, recently the necessity of the Pringle manoevre has been a
matter of debate due to the increasing perception of ischemic/
reperfusion damage of remaining liver tissue. Different dissection
techniques and selective vascular clamping or ligation seem to reduce
the importance of the Pringle manoevre. PATIENTS AND
METHODS: From 01/2001 to 08/2004, 390 patients underwent
laparotomy due to liver tumors; the main indication was liver
metastases. Helix Hydrojet or Ultrasound selector were used
routinely for the parenchyma dissection. In some resections a stapler
device or TissueLink device was used. 32 right and left hepatec-
tomies, 103 sectorectomies or segmentectomies and 151 atypical
resection were analysed. Other treatments like isolated liver per-
fusion, local ablative treatments (cryodestruction, radiofrequency)
and transplantations were excluded. RESULTS: The total Pringle
manoevre was necessary in only 10.6% due to bleeding, in 63.6%
selective extrahepatic vascular clamping and in 25.8% no vascular
clamping was used. There was no significant difference of the
resection type or the mean blood loss in resection without vascular
clamping or with selective extrahepatic clamping compared to the
Pringle group. CONCLUSION: Pringle manoevre is not routinely
necessary in hepatic resection using the available techniques for
tissue division. Extrahepatic vascular clamping can reduce ischemic/
reperfusion injury and demonstrate the segmental or sectorial lines
for anatomical resection.
21 QUANTITATIVE ANALYSIS OF CANCER CELL
DISSEMINATION DURING CURATIVE SURGERY FOR
COLORECTAL LIVER METASTASES, AND ITS IMPACT ON
CANCER RECURRENCE
Topal B3, Aerts JL1, Fieuws S2, Penninckx F3, (1) Laboratory of
Experimental Medicine; (2) Laboratory of Biostatistics;
(3) Departments of Abdominal Surgery, University Hospital
Gasthuisberg, Leuven, Belgium
INTRODUCTION AND AIM: The majority of patients with
colorectal liver metastases (CRLM) will develop recurrence follow-
ing potentially curable surgery. The amount of cancer cells disse-
minated during curative surgery may be responsible for recurrence.
Haematogenous and intrahepatic cancer cell dissemination was
evaluated, and its impact on cancer recurrence was assessed.
PATIENTS AND METHODS: Twenty patients with 31 resectable
CRLM were included in a prospective study. Cancer cell dissemi-
nation was determined before, during and after surgery using ‘real-
time’ quantitative RT-PCR assay, based on detection and quantifi-
cation of CEA and CK20 mRNA transcripts. RESULTS: Following
surgery circulating cancer cells were detected in 80% and intra-
hepatic cancer cells in 37% of the patients. Also the amounts of
disseminated cancer cells were significantly increased after surgery as
compared to the pre-operative levels. Neither haematogenous nor
intrahepatic cancer cell dissemination was related to cancer recur-
rence. CONCLUSION: In this small patient series, curative surgery
for CRLM significantly increased the amount of disseminated cancer
cells, although without prognostic relevance.
22 LIVER METASTASES FROM GASTRIC CANCER—IS
SURGERY JUSTIFIED?
Muratore A, Vigano L, Amisano M, Capussotti L, Surgical
Oncology, Instituto per la Ricerca e la Cura del Cancro,
Candiolo (To), Italy
INTRODUCTION AND AIM: The liver is a common site of distant
metastases from gastric carcinoma but long-term benefit of hepatic
resection is still controversial. PATIENTS AND METHODS: We
have retrospectively analysed the outcome and the prognostic factors
of 14 patients who underwent liver resection for metastases from
gastric cancer. RESULTS: Resection was curative in 12 cases. Nine
patients (64.3%) underwent synchronous gastric and liver resection;
in the remaining five, the median time to liver resection was 26.7
months. There was no in-hospital mortality in our series. There was a
trend toward an increased rate of complications in the synchronous
group but the difference was not significant. The overall and median
survival from the time of liver resection were 40.8% at 3 years and
14 months. By the end of follow-up, four of the nine synchronous
patients are alive (three without disease) at 13, 28, 29, and 35 months
respectively. CONCLUSION: Long-term survival can be achieved
by radical resection of gastric cancer liver metastases, even in the
subset of patients with synchronous resectable liver metastases.
23 LIVER RESECTION FOR COLORECTAL METASTATIC
SECONDARIES: PROGNOSTIC FACTORS
Karamarkovic AR, Djukic V, Radenkovic D, Jeremic V, 3rd surgical
Department, University Center for Emergency Surgery, Belgrade,
Serbia & Montenegro
INTRODUCTION AND AIM: Liver resection currently serves as
the only curative therapy for liver metastases from colorectal
carcinoma. Appropriate criteria for surgical resection are contro-
versial. The aim of this study was to determine the characteristics
of the disease which affected prognosis. PATIENTS AND
METHODS: Between 1999 and 2004, 95 patients with hepatic
metastases from colorectal carcinoma underwent anatomical liver
resection at our institution. The follow-up period ranged from 2 to 60
months. The survival rate was estimated by the Kaplan-Meier
method and compared by log-rank test. RESULTS: 56 of the
primary lesions were located in the colon and 39 in the rectum. There
were 33 Dukes B, 43 Dukes C and 19 Dukes D. Liver metastases
were detected synchronously in 29 and metachronously in 66
patients at the time of diagnosis. The operative mortality rate within
30 postoperative days was 0%. During the follow-up period we
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registered a tumor recurrence rate of 14.1%. The overall 5-year
survival rate was 36.9%. Multivariate analysis shows a significant
correlation between 3-year survival and solitary ( p-0.031) and
unilobar ( p-0.014) metastases. The survival rate did not significantly
correlate with gender, age, location of primary tumor, Dukes classi-
fication, time of diagnosis or CEA level. CONCLUSION: According
to our results, number and localization of metastatic liver lesions
represents the prognostic factors of significant importance
( p50.03). Without an effective therapeutic alternative, liver
resection is still recommended and represents a “gold standard” in
the treatment of colorectal liver metastases.
24 INTRAOPERATIVE RADIOFREQUENCY ABLATION
(RFA) AS THERAPEUTIC OPTION FOR IRRESECTABLE
LIVER METASTASIS OF COLORECTAL CANCER
Hinz S, Tepel J, Fa¨ndrich F, Clinic for General and Thoracic
Surgery, University Hospital Schleswig-Holstein, Campus Kiel,
Kiel, Germany
INTRODUCTION AND AIM: We evaluated the outcome of
patients with irresectable colorectal liver metastasis (CLM) who
received radiofrequency ablation (RFA) at laparotomy. PATIENTS
AND METHODS: Twenty-nine patients with a variety of liver
malignancies were found to be unsuitable for complete tumour
resection at explorative laparotomy and were treated with intra-
operative RFA with or without additional liver resection. Clinical
course and follow-up were documented prospectively. CT scan was
performed at 6 and 12 weeks postoperatively and at 6-month inter-
vals thereafter. A subgroup of 20 patients with CLM was analysed for
the present study. RESULTS: In 20 patients 60 liver metastasis were
treated. Out of these, 38 were treated with RFA and 22 resected. The
mean diameter of the treated metastasis was 3.9 cm with a maximum
of 10 cm. 10 patients received combined treatment of RFA and
resection. The median follow-up was 18 months (4–46 months).
80% (16/20) of the patients developed liver metastasis at different
sites, reflecting the disseminated tumour stage with occult metastasis
having developed already at the time of the operation. 30% of the
patients developed extrahepatic tumour progress. Half of the patients
have died so far. With a median survival of 21.5 months, survival rates
at present are 82% (14/17) and 46% (6/13) after 1 and 2 years. In 5 of
20 patients tumour relapse at the site of former RFA was diagnosed,
reflecting a long-term local control rate of 75%. CONCLUSION:
Intraoperative RFA extends the scope of surgical options in otherwise
irresectable CLM. Long-term benefit is substantially limited by
disseminated tumour progress.
25 THE CLINICAL RISK SCORE IN DETERMINING
RESECTABILITY OF HEPATIC COLORECTAL METASTASES
Mann C, Neal C, Metcalfe M, Pattenden C, Dennison A, Berry D,
Department of Hepatobiliary Surgery, Leicester General Hospital,
Leicester, UK
INTRODUCTION AND AIM: The clinical risk score (CRS),
originally proposed by Fong et al., has been shown to be highly
predictive of patient outcome and survival post-hepatic resection for
colorectal metastases. The aim of this study was to determine
whether the same score could be used to predict unresectable disease
prior to laparotomy. PATIENTS AND METHODS: All patients
undergoing a hepatic resection for colorectal metastases during a 3-
year period (October 2001–October 2004) were identified from our
hepatobiliary database. A preoperative CRS was determined for each
patient, derived from 5 independent prognostic criteria: nodal status
of the primary lesion, disease-free interval, number of hepatic
metastases, size of the largest metastasis, and preoperative carci-
noembryonic antigen level. This was then correlated with the
outcome at laparoscopy and laparotomy. RESULTS: 169 patients
were identified. 114 (68%) patients had resectable disease (median
CRS=2), 55 (32%) were found to be unresectable at either laparo-
scopy or laparotomy (median CRS=3). Dividing the patients into
low-risk (0–2) and high-risk (3–5) CRS, the likelihood of proceeding
to resection in the low-risk and high-risk groups was significantly
different ( p50.001; 88% cf. 46%). CONCLUSION: The CRS is
useful in predicting resectability for hepatic colorectal metastases,
and so detailed preoperative staging of patients with scores of 3–5 is
suggested.
26 CHANGES IN SYMPATHETIC BETA-ADRENERGIC
RECEPTOR EXPRESSION AND FUNCTION IN HUMAN
COLORECTAL CANCER HEPATIC METASTASES
Kassahun W4, Ungemach F1, Abraham G1, Gottschalk J2,
Schutz A3, Hauss J4, (1) Pharmacology; (2) Physiological Chemistry;
(3) Pathology; (4) Surgery II, University of Leipzig, Leipzig,
Germany
INTRODUCTION AND AIM: Hepatic metabolic pathways
are regulated by the sympathetic-catecholamine system mainly
through cAMP-linked beta2-adrenoceptors (beta2-ARs) in humans
and to a lesser extent through cAMP-independent mechanisms,
but there has been little investigation as to whether beta2-ARs and
their signaling pathways play a role in colorectal cancer hepatic
metastases. PATIENTS AND METHODS: Changes in number
and distribution of beta-ARs as well as in post-receptor signaling
components were studied in membranes of human liver with
colorectal cancer hepatic metastases (CRCHM), and for compar-
ison, in membranes of non-adjacent, non-metastatic human liver
(NA-NM) obtained from 13 patients, using [125I]-iodocyano-
pindolol (ICYP) binding and competition studies. The hepatic beta-
adrenergic receptor coupling to adenylate cyclase (AC) was assessed
by the conversion of [alpha-32P]-ATP to [alpha-32P]-cAMP in
human liver membranes induced by isoproterenol plus GTP,
foskolin or sodium fluoride. RESULTS: In CRCHM, the number of
beta-ARs (Bmax) was significantly reduced, compared with NA-NM
liver tissues (40.09+2.83 vs 23.09+3.24 fmol/mg protein;
p50.001), whereas the affinity of ICYP binding to the receptor
remained unaffected. Desensitized beta-ARs were uncoupled from
stimulatory G-protein (GS), as total number of beta-adrenoceptors
in the high affinity state was significantly reduced in human
CRCHM. Concomitantly, CRCHM elicited decrease in the catalytic
AC activity (cAMP formation) in response to isoproterenol plus
GTP or forskolin or NaF. CONCLUSION: These data show
that the hepatic beta-AR-G-protein(s)-adenylate cyclase signaling
system was markedly impaired in CRCHM, and thus, might
play an important role in mediating ALTERED Beta-AR-mediated
liver metabolism, such as glucose homeostasis, during tumor
progression.
27 ACUTE LUNG INFLAMMATION FOLLOWING
HEPATIC ABLATION: A COMPARISON OF DIFFERENT
ABLATIVE MODALITIES
Ahmad F1, Strickland A1, Sayers R2, Beckingham I3, Lloyd D1,
(1) Department of Hepatobiliary Surgery, Leicester Royal Infirmary,
Leicester UK; (2) Department of Surgery, University of Leicester,
Leicester, UK; (3) Department of Surgery, Queens Medical Centre,
Nottingham, UK
INTRODUCTION AND AIM: Multi-organ dysfunction syndrome
(MODS) resulting from an exaggerated systemic inflammatory
response (SIRS) has been observed following hepatic cryotherapy.
Alternative techniques such as radiofrequency ablation (RFA) and
microwave tissue ablation (MTA) have been developed, although
their effect on the pulmonary system following large volume ablation
remains unknown. PATIENTS AND METHODS: Following
laparotomy, adult rats underwent ablation or resection of 15%, 33%
or 66% of the total liver volume. At 48 hours post-procedure, the
animals underwent terminal anaesthesia. One lung was removed to
determine the wet/dry lung ratio; broncho-alveolar lavage (BAL) was
performed on the remaining lung and examined for the presence of
inflammatory cells and total protein content. Lung sections were
taken for histological assessment. RESULTS: All animals survived to
48 hours except those in the 66% cryoablation and RFA groups,
which all died within 6 hours. Significantly increased wet/dry lung
ratios were only found in the 33% and the 66% cryoablation groups
and 66% RFA group. Greater numbers of inflammatory cells were
present in the 33% and 66% cryoablation groups and also the 66%
RFA group. These three groups also exhibited an increase in the BAL
total protein content. Histology revealed multiple foci of inflamma-
tory cells in the lung following 66% cryoablation and RFA, but these
were absent in the 66% resection and MTA groups. CONCLU-
SION: Small volumes of hepatic resection or ablation by cryother-
apy, RFA or MTA do not appear to cause significant lung injury.
However, larger volumes of hepatic cryotherapy and RFA induce
lung injury associated with a high mortality in these small animal
models.
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28 HEPATIC RESECTIONS FOR COLORECTAL
METASTASES AND ALLOGENIC TRANSFUSION:
MORBIDITY AND NOSOCOMIAL INFECTIONS RATES
Serrablo A1, Lopez-Molina L, De la Cruz JM, Esarte J, Borlan S,
Serrablo L, HPB Unit, Miguel Servet University Hospital, Zaragoza,
Spain
INTRODUCTION AND AIM: There is currently a growing inter-
est in the analysis of the effects of allogenic blood transfusion (ABT)
in oncologic surgical patients about morbidity, mortality, disease-free
interval, survival, ICU and hospital stays. Allogenic transfusion in
these patients arises as an independent risk factor in the outcome.
The 30 last major hepatectomies for colorectal metastases with
curative intention and peroperatory transfusion were analyzed.
PATIENTS AND METHODS: We selected from a prospective
database the last 30 major hepatectomies for colorectal metastases
with perioperative transfusion. The major liver resection with cura-
tive intention, perioperative transfusio´n and the ASA score were
included. The morbidity, nososcomial infection rate, length of ICU
stay and hospital stay were analyzed according to autologous
or allogenic transfusion. RESULTS: The mean age was 64 years
(range 21–80), 20 male and 10 female. All of them had an ASA
score of III. The extended postoperative mortality (2 months) was
0%. The mean surgical time was 283 minutes, the preoperatorive
haemoglobin and haematocrit values were 12.93 g/l and 38.6%. The
mean length of ICU stay was 3 days and hospital stay was 14.2 days.
The nosocomial infecction rate was 13%, the overall morbidity rate
was 26.6%. According to allogenic or autologous transfusion we
analyzed some variables. ICU stay depending on allogenic or auto-
logous group was 4.6 and 2.2, respectively, and the length of hospital
stay was 20.7 and 9.1 days. The NI rates were 30% vs 0%, and
morbidity was 53,.% vs 5.9%. CONCLUSION: Possibly the allo-
genic transfusion in these patients supposes a morbidity risk that
increases the length of ICU stay and the hospital stay.The use of
blood-saving means and restrictive transfusion approaches should be
outlined in these patients as part integrated inside the oncologic
treatment.
29 LIVER RESECTION FOR METASTATIC
BREAST CANCER
Thelen A1, Jonas S1, Benckert C1, Sehouli J2, Rudolph B3, Neuhaus
P1, (1) Department of General, Visceral and Transplant Surgery;
(2) Department of Gynecology; (3) Department of Pathology,
Charite-University Medicine, Berlin, Germany
INTRODUCTION AND AIM: Liver metastases of breast cancer
usually indicate the presence of disseminated cancer with a very poor
prognosis. Resection is rarely performed and few reports have
addressed the results of surgical treatment for breast cancer meta-
static to the liver. The aim of our study was to analyse the outcome of
patients with metastatic breast cancer after resection of isolated
hepatic secondaries and to identify selection criteria for patients with
a long-term benefit. PATIENTS AND METHODS: Thirty-one
patients with breast cancer liver metastases underwent resection
between January 1988 and August 2004. Results of this treatment are
reported, together with analysis of clinical, pathological and tumor-
specific parameters as prognostic factors for survival. RESULTS:
The mean age of the patients was 55+10.7 years. No patient died in
the postoperative period and 13% (n=4) developed complications.
Resection was considered to be formally curative in 81% (n=25) of
cases. The 1-, 5- and 10-year survival rates for all patients in this
series were 77%, 41% and 33%, respectively. The survival rate
differed according to the age at the time of liver resection with an
inferior survival in patients younger than 45 years. Interestingly, time
to onset of metastases and tumor-specific parameters, like nodal
status of the primary and number of metastases, had no influence on
long-term survival. CONCLUSION: These data suggest that liver
resection for breast cancer metastases needs careful patient selection,
but can offer some patients a chance of long-term survival, which is
not inferior to patients with colorectal liver metastases.
30 OUTCOME AFTER RESECTION OF COLORECTAL
LIVER METASTASES
Meimarakis G2, Schauer R1, Radaj A2, Vahedi N2, Jauch KW2,
Loehe F2, (1) Department of Surgery, Klinikum Traunstein,
Traunstein, Germany; (2) Department of Surgery, Ludwig-
Maximilians-University of Munich, Klinikum Grosshadern,
Munich, Germany
INTRODUCTION AND AIM: Only 30% of patients with liver
metastases are suitable for liver resection. The actuarial survival after
liver resection for colorectal metastases ranges between 20% and
45% after 5 years due to different selection criteria. The purpose of
the present study was to evaluate the results and predictors of
outcome after resection of liver metastases. PATIENTS AND
METHODS: 312 patients with metastases from colonic cancer
(n=196) and rectal cancer (n=116), who underwent liver resection
between 1990 and 2002 were analysed retrospectively using our
database. RESULTS: Morbidity and mortality after liver resection
were 9.5% and 3.5%, respectively. Overall survival was 23% after 5
years, but actuarial survival increased significantly in 234 patients
after curative resection (histologically tumour-free resection margin)
up to 34% after 5 years compared to patients with tumour residual
after resection (log rank p50.005). Patients with a maximum of
3 metastases (n=145) had a significantly better outcome of 38%
survival after 5 years compared with patients with more than 3
metastases (log rank p50.03). Multivariate analysis revealed that
DFI 512 months, 43 metastases and tumour infiltration of the
resection margin represent negative predictors for the outcome after
liver resection. UICC stage of the primary tumour had no influence
on the survival after resection of liver metastases. CONCLUSION:
All patients with liver metastases should be evaluated for liver
resection independent of the primary tumour stage. Further studies
are needed to investigate if patients with negative predictors may have
a benefit from chemotherapy after liver resection.
31 RADIOFREQUENCY ENERGY CAN COMPLETELY
DESTROY SELECTED RESECTABLE LIVER METASTASES
FROM COLORECTAL CANCER
Hompes D1, Topal B1, Roskams T2, (1) Department of Abdominal
Surgery; (2) Departments of Abdominal Surgery and Pathology,
University Hospital Gasthuisberg, Leuven, Belgium
INTRODUCTION AND AIM: Radiofrequency ablation (RFA) of
liver malignancies is associated with minimal morbidity and mortality
as compared with hepatic resection. However, the use of RFA for
colorectal liver metastases (CRLM) is limited to patients with
unresectable disease, because there is major concern about the
completeness of tumour destruction by RFA. In the present study
the completeness of RFA is assessed in selected patients with resect-
able CRLM. PATIENTS AND METHODS: In eight patients 10
resectable CRLM with a median (range) diameter of 35 (25–42) mm.
were treated with RFA immediately followed by surgical resection.
As mitochondrial abnormalities are the earliest findings observed
after ischemic injury, the completeness of RFA was assessed using an
anti-mitochondrial monoclonal antibody, MAB1273, for immuno-
histochemical staining, and using haematoxylin and eosin (H&E)
staining. RESULTS: Resected specimens were sliced at 4-mm
intervals and entire cross-sections were analysed. In all specimens the
margins were free of tumour on macroscopic and histopathologic
examination. Using H&E and anti-mitochondrial staining no viable
cells were found either in the metastasis itself or in hepatic
parenchyma around the tumour treated with RFA. CONCLUSION:
In contrast to other studies, the intent of the RFA treatment in the
present study was to completely destroy the entire CRLM. Complete
tumour destruction was obtained in all 10 CRLM treated with RFA.
These findings may be a basis for clinical trials to compare the
oncological outcome following surgical resection vs RFA in carefully
selected patients with resectable CLRM.
32 BILIARY CARCINOEMBRYONIC ANTIGEN AS
PREDICTIVE FACTOR OF METACHRONOUS LIVER
METASTASES OF COLORECTAL CANCER
Puleo S, Zappala` O, Portale TR, Di Carlo I, Consoli AM,
Li Destri G, Surgical Sciences, University of Catania, Catania, Italy
INTRODUCTION AND AIM: The 20–30% of metachronous liver
colorectal cancer are present as the metastases from time of surgical
operation of the primary tumor as occult metastases and will be
discovered in the follow-up; unfortunately only 30% of these patients
can be submitted to a curative liver resection because of number, size
and site of metastases. The aim of this prospective study was to
evaluate the role of intraoperative biliary CEA as an early predictive
factor of future growth of liver metastases leading to modification of
our therapeutical strategy. PATIENTS AND METHODS: 100
patients affected by colorectal cancer and undergoing curative
surgery were submitted during the operation to sampling of bile from
the gallbladder by fine needle aspiration. The determination of biliary
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CEA was assessed by an immunoenzymatic method suggested by
Paul. The patients were submitted to a follow-up program over the
next 3 years to correlate the value of biliary CEA to the appearance of
liver metastases in each patient. RESULTS: Eighty-nine patients
were followed up for 3 years; 11 patients dropped out. 78 patients did
not show liver metastases, 73 of these had a normal value of intra-
operative biliary CEA (n.v. 0–2 ng/ml) and a pathological value in the
other 5 patients. 11 patients, 9 with high value of biliary CEA and 2
with normal values, developed liver metastases. Diagnostic sensi-
tivity, specificity and accuracy were 81.8%, 93.6% and 92.13%,
respectively. CONCLUSION: Intraoperative determination of bili-
ary CEA seems to be an effective prognostic factor to predict the
onset of metachronous liver metastases and point out the possibility
of occult metastases which could be treated by intraportal regional
chemotherapy already at the time of surgery of the primary tumor.
33 RADIOFREQUENCY THERMAL ABLATION IN THE
TREATMENT OF INOPERABLE COLORECTAL LIVER
METASTASES: A 3-YEAR, SINGLE-CENTER EXPERIENCE
Zadrozny D1, Sledzinski Z1, Studniarek M2, Nowakowski M2,
Gorycki T2, Adamonis W1, Stefaniak T1, (1) Dept of General and
Endocrine Surgery and Transplantation; (2) Dept of Radiology,
Medical University of Gdansk, Poland
INTRODUCTION AND AIM: Liver is a frequent site of colorectal
cancer (CRC) metastases (about 60% of cases) and in 30–50% of
them, the only one. Liver resection can be done as a curative
approach in only about 10% of patients. The prognosis for the other
group is poor; even with use of modern aggressive chemotherapy the
median survival of about 11 months is noted. The aim of this study
was to evaluate the safety and efficacy of radiofrequency thermal
ablation in the treatment of CRC liver metastases. PATIENTS AND
METHODS: Between April 2001 and April 2004, 144 patients
(70 F and 74 M) with CRC metasases were treated using percuta-
neous radiofrequency thermal ablation (PRFTA). All were disqua-
lified from liver resection. The diameter of treated tumors varied
from 2 to 8 cm, the number from 1 to 8. In 85 cases there were
synchronic lesions, in 59 these were metachronic. The majority of
patients received standard chemotherapy (5-Fu+Lv). RESULTS:
There were no intraoperative complications; in one patient a large
bowel thermal injury caused intraperitoneal abscess. No early
mortality was noted. The observation period was 2–35 months
(average 12.3). The mean survival time observed (from the first
PRFTA) was 17 months; 1- and 2-year survival rates were 72% and
34%, respectively. No differences between synchronic and meta-
chronic tumors were noted. Tumor number and size correlated
negatively with survival. There was no impact on health-related
quality of life in our patients. CONCLUSION: PRFTA is a safe
method for treating of CRC liver metastases and improved life
expectancy in these patients.
34 SIGNIFICANCE OF PERIOPERATIVE FACTORS ON
MORBIDITY AND MORTALITY OF LIVER RESECTION FOR
COLORECTAL METASTASES
Mennigen RB, Bru¨wer M, Albuquerque M, Senninger N,
Krieglstein CF, Klinik und Poliklinik fu¨r Allgemeine Chirurgie,
Universita¨tsklinikum Mu¨nster, Mu¨nster, Germany
INTRODUCTION AND AIM: Liver resection offers the only
curative therapy for patients with liver metastases from colorectal
carcinoma. In this study morbidity and mortality of liver resection for
colorectal metastases were studied retrospectively. Laboratory
parameters were examined to identify possible predictors of peri-
operative morbidity/mortality. PATIENTS AND METHODS:
During 3 consecutive years, 70 patients with liver metastases from
colorectal carcinoma [mean age: 61.5 years (43–82), median: 61,
SD: 9.1] underwent resection with curative intent. For each patient
surgical data, preoperative laboratory parameters, morbidity and
mortality were recorded. The influence of perioperative factors on
morbidity and mortality was tested with the chi-squared test
( p50.05). RESULTS: Perioperative morbidity was 35.7% (25/70),
with minor complications (wound infection, pleuritis) occuring in
18.6% (13/70) and major complications (bleeding, abscess, liver
failure, peritonitis, bile leakage) occurring in 17.1% (12/70),
respectively. Perioperative mortality was 2.9% (2/70). The mean
postoperative hospital stay was 15.3 days (SD: 10.2). Morbidity of
minor resections (up to 2 liver segments, n=46) was significantly
lower than that of major resections (3 and more liver segments,
n=24): 26.1% vs 54.2% ( p50.05), respectively. Preoperative
laboratory parameters (hemoglobin, bilirubin, AST, ALT, GGT,
albumin, PT, PTT) and liver function measured by 13C-methacetin
breath test showed no correlation with morbidity and mortality.
CONCLUSION: Morbidity and mortality closely depend on the
extent of necessary liver resection. Predictors of perioperative
morbidity could not be identified among the preoperative laboratory
parameters. Indication for liver resection must therefore be evaluated
considering individual patient-related risk factors.
35 APROTININ INHIBITS LOCAL PLATELET TRAPPING
AND IMPROVES TISSUE DESTRUCTION IN HEPATIC
CRYOSURGERY
Kollmar O2, Czyborra J1, Dietrich S2, Schilling MK2, Kirsch CM1,
Richter S2, Menger MD3, Pistorius GA2, (1) Department of Nuclear
Medicine; (2) Department of General, Visceral, Vascular and
Pediatric Surgery; (3) Institute for Clinical & Experimental Surgery,
University of Saarland, Homburg/Saar, Germany
INTRODUCTION AND AIM: During the last decade cryosurgery
became an interesting alternative in the treatment of non-resectable
liver tumors. The freeze-thaw procedure, however, may be asso-
ciated with life-threatening thrombocytopenia due to local platelet
trapping, and success of tumor ablation may be compromised
by inadequate parenchymal cell destruction. PATIENTS AND
METHODS: Because aprotinin is capable of inhibiting the initiation
of both coagulation and fibrinolysis, we herein studied by whole body
scintigraphy of Indium-111-labelled platelets and histomorphology
in a porcine model of hepatic cryosurgery whether this serine protease
inhibitor is effective in attenuating platelet trapping and improving
tissue destruction. RESULTS: Fifteen minutes of cryotherapy
(7168C at the tip of the cryo-probe) induced a 30; 4 cm3 cryole-
sion, which presented with massive platelet trapping (14.0; 1.7%
cryolesion activity/whole body activity) and incomplete parenchymal
cell destruction (0.9; 0.3; score of hepatocyte nuclear destruction
within the margin of the cryolesion). Aprotinin treatment, i.e.
500 000 IU initial bolus injection and additional 500 000 IU infu-
sion over 3 h, did not affect the size of the cryolesion (29; 3 cm3), but
was capable of reducing local platelet activity (1.9; 1.9%; p50.001)
and inducing hepatocyte nuclear destruction (3.0; 0.0; p50.001).
CONCLUSION: Our study indicates that aprotinin (i) inhibits
cryoablation-associated platelet trapping and (ii) improves tissue
destruction. The serine protease inhibitor may represent a valuable
adjunct in cryosurgery of hepatic tumors.
36 SURGERY FOR LIVER METASTASES FROM
COLORECTAL CANCER
Uggeri F1, Crippa S2, Caprotti R1, Angelini C1, Bonardi C1,
Mussi C1, Fontana A1, Uggeri F1, (1) Surgery, University of
Milan-Bicocca, Milan, Italy; (2) University of Verona, Surgery,
Vimercate (MI), Italy
INTRODUCTION AND AIM: Liver resection is the only poten-
tially curative treatment currently available for liver metastases from
colorectal cancer. This is a retrospective study examining surgical
treatment and survival of patients undergoing surgery for colorectal
liver metastases at a single center. PATIENTS AND METHODS:
From January 1992 to December 2002, 135 patients (81 male, 54
female, mean age 65, range 43–80) with liver metastases from
colorectal cancer have been treated at our institution. The variables
included in the study were: patients’ characteristics, type and features
of surgical procedures, patients’ survival. Resection of 3 or more
segments was defined as a major hepatectomy. Liver resection was
defined as curative in case of negative resection margin and no
extrahepatic disease. The median follow-up was 36 months (range
12–112 months). RESULTS: Primary colorectal cancer was resected
in all cases. Curative resections were attempted in 122 patients. 47
metastasectomy and wedge resections (38.5%), 19 segmentectomies
(15.5%), 17 bisegmentectomies (14%) and 39 major hepatectomies
(32%) were performed. The mean blood loss was 900 ml
(range:100–2600); the mean hospital stay was 13 days (range 8–30).
Postoperative complications appeared in 23 patients (15%), the most
frequent was pleural effusion (14 cases). In 6 patients a second
laparotomy was required. The overall postoperative mortality was
3.2% (5/135 patients). The 3- and 5-year overall survival was 42%
and 25% with disease-free survival of 21%. CONCLUSION: In
appropriately selected patients liver resection for colorectal cancer
metastases is a safe and effective treatment with acceptable morbidity
and low perioperative mortality.
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37 4-YEAR EXPERIENCE OF PERCUTANEOUS
CT-GUIDED RADIOFREQUENCY ABLATION FOR
COLORECTAL LIVER METASTASES
George S3, Karaliotas C1, Thanos L2, Mylona S2, Christofidis T3,
Lilis C3, (1) Surgical Oncology Uni; (2) Radiology; (3) 2nd
Department of General Surgery, Red Cross Hospital, Neo Psychico,
Athens, Greece
INTRODUCTION AND AIM: A retrospective study of 57 patients
with metastatic liver tumors of colorectal origin, treated with radio-
frequency ablation (RFA), in a 4-year period. PATIENTS AND
METHODS: From May 2000 to August 2004, we applied RFA
under CT guidance in 57 patients deemed to be unresectable in 142
sessions. We used a Rita device with 7–9 foldable electrodes. Each
session lasted 15–17 min and the target temperature was set at 95C.
Lesion diameter ranged from 1 to 6 cm. Follow-up was made at 1, 3,
6, 12 and 24 months with dual-phase contrast-enhanced spiral CT
and tumor markers. Aiming to increase resectability, we combined
RFA with portal vein embolization (PVE) and transarterial
chemoembolization (TACE) in the last 6 months in 8 of our patients.
RESULTS: Average follow-up was 15 months. Procedural mortality
was nil. A decreased in tumor markers was noticed in 81.8% of
patients. Lesions recurring at RFA site were 7.7%. New metastases
developed in 27.7%. Complications included peritoneal hemorrhage
in two patients and intrahepatic abscess in one patient. Median
survival was 28 months. Hepatectomy was feasible in 3 of 8 patients
treated with RFA, PVE and TACE. CONCLUSION: Percutaneous
CT-guided RFA for metastatic liver tumors of colorectal origin is a
safe and effective treatment in patients with unresectable liver lesions.
38 IS PERCUTANEOUS THERMAL ABLATION A
SOLUTION FOR PATIENTS WITH INTRAHEPATIC
RECURRENCE AFTER LIVER RESECTION FOR
COLORECTAL METASTASES?
Zadrozny D1, Sledzinski Z1, Studniarek M2, Stefaniak T1,
Adamonis W1, Gorycki T2, Nowakowski M2, (1) Department of
General and Endocrine Surgery and Transplantation;
(2) Department of Radiology, Medical University of Gdansk, Poland
INTRODUCTION AND AIM: Liver resection remains the ‘gold
standard’; for patients with colorectal liver metastases, but even after
curative resections intrahepatic recurrences are frequent. Re-resec-
tion may prolong a patient’s life expectancy but is often not possible
due to anatomical reasons and/or inadequate liver function. Percu-
taneous radiofrequency thermal ablation (PRFTA) may be useful for
local control of liver cancer foci. The aim of this study was to evaluate
the safety and efficacy of PRFTA as a treatment for intrahepatic liver
recurrence after liver resection due to colorectal liver metastases.
PATIENTS AND METHODS: Between April 2001 and April
2004, 144 patients with colorectal liver metastases were treated using
PRFTA. 20 of them qualified for this procedure due to local recur-
rence after liver resection. All of them were disqualifed from re-
resection in experienced liver sugery centers. All patients with
extrahepatic disease, except one with a solitary pulmonary tumour
(resected 2 months later), did not qualify for the procedure. The
mean number of foci in liver remnant was 2.4 (1–4), mean size
3.2 cm (2–4). RESULTS: The median survival time computed in
the whole group of patients with colorectal liver metastases was
17 months, where in patients treated due to hepatic recurrence 23
months. The difference was significant. CONCLUSION: Our data
suggest that PRFTA may be useful in the treatment of liver recur-
rence after resection. The survival seems to be better than in patients
without previous resection, but the number of observed patients is




Severtsev AN, Tchudaev D, Mejgih T, HPB-Surgery, Central
Clinical Hospital #1 OAO RZD, Moscow, Russia
INTRODUCTION AND AIM: The basic goal of all regional
chemotherapy, including intraperitoneal chemotherapy, is to
increase the total amount of drug delivered to the tumor while
decreasing the amount of drug reaching the systemic circulation. A
pharmacokinetic advantage exists for larger, water-soluble and
ionized molecules when administered by the intraperitoneal route.
An important route of clearance from the peritoneal cavity is by
portal circulation. Some drugs, such as 5-FU, are then metabolized
into nontoxic forms during the first pass through the liver. Hepatic
metabolism on the first pass adds an additional pharmacokinetic
advantage. Also, systemically delivered neutralizing agents may be
administered to minimize the toxic side effects of intraperitoneal
chemotherapy. Most patients with colorectal cancer at the time of
diagnosis had liver metastases (MTS). Now Irinotecan is one the
most prospective drugs for the treatment colorectal cancer. The
purpose of this study was to assess the clinical results of intraperi-
toneal chemotherapy with Irinotecan for metastatic liver colorectal
cancer. PATIENTS AND METHODS: From December 2001 to
February 2004, 9 patients with metastatic liver colorectal cancer had
postoperative intraperitoneal chemotherapy with Irinotecan at the
Department of Hepato-Pancreato-biliary Surgery; Central Clinical
Hospital of the MPS, Moscow, Russia. The male/female ratio was 9/
0. Mean age of patients was 65.10 years. The main site of cancer
(colon or rectum) was resected. All patients had a colostomy. All
patients had non-resectable bilobar liver MTS. An intraperitoneal
catheter with subcutaneous port was inserted during the main
surgery or just after the surgery (under local anesthesia). 3 weeks after
surgery patients had intraperitoneal chemotherapy: Irinotecan
(Campto, Aventis) iv 400 mg/m2. The number of courses was up to
11. RESULTS: All patients are alive. Liver nodules (MTS) have
disappeared or their size has significantly reduced; 3 patients had
colostomy closure. CONCLUSION: Intraperitoneal chemotherapy
with Irinotecan could be a good challenge for patients with advanced
colorectal cancer even if liver nodules are not resected.
40 THE MULTIDISCIPLINARY MANAGEMENT OF
COLORECTAL CANCER LIVER METASTASES
Chu CW1, Kim HC1, Lim CV1, Shin EJ1, Cho GS1, Yu KW1,
Song OP1, Hong DS2, Park SJ3, Cho JH3, Lee HK3, Kim HK4,
Kwon KW4, Koh ES4, (1) Surgery; (2) Oncology; (3) Radiology;
(4) Pathology, Soonchunhyang University Hospital, Jung-Dong,
Wonmi-Gu, Bucheon-Si, Gyeonggi-Do, South Korea
INTRODUCTION AND AIM: Liver metastases are the main cause
of death in colorectal cancer (CRC). The median survival of
untreated patients is 51 year and the median survival of chemo-
therapy patients is not more than 18 months. Their increasing
survival is only achieved by aggressive surgical resection. However,
resectability is 520% and the recurrence rate is 470% after resec-
tion. At least half of the recurrences arise in the liver. Therefore, there
are three points important to improving survival of patients with
CRC liver metastases (CRCLM). The first point is accurately
detecting lesions preoperatively. The second important factor is
complete surgical removal. The last one is the usage of optimal
adjuvant chemotherapy. The aim of this study was to assess our
processing of 10 cases of CRCLM. PATIENTS AND METHODS:
10 patients with CRCLM were managed at our institution from
August 2003 to October 2004. Their hospital records were reviewed
retrospectively. RESULTS: Early recurrence developed in initially
experienced 2 cases after liver resection. Its causes were supposed to
be due to inaccurate lesion detectection and inappropriate adjuvant
chemotherapy. Therefore, the authors tried to detect metastases
lesions accurately. A US specialist performed IOUS from the third
case and Feridex-enhanced MRI scanning was performed from the
6th case on. 7 cases received sequential regional and systemic
chemotherapy. Bilobar liver metastases were found in 5 cases and 2
cases had lesions 45 cm. The greatest number of metastases was
14. In that case, the authors performed two-stage hepatectomy
combined with expansion of the liver volume growing. The second
highest number was 8 metastases. In that case, left hepatectomy was
performed for 3 metastases in the left lobe. Wedge resection and RFA
were performed for 5 metastases in the right lobe. No evidence of
recurrence was found in 8 cases except for the initially experienced
2 cases. CONCLUSION: Although a long period of follow-up is
needed, accurate lesion detection, aggressive surgical resection, and
optimal adjuvant chemotherapy might be essential to decrease
recurrence and to increase survival in CRCLM.
41 COMBINED HEPATOPANCREATODUODENECTOMY
FOR METASTATIC DUODENAL GASTROINTESTINAL
STROMAL TUMOUR
Stratopoulos C1, Soonawalla Z1, Piris J2, Sica G1, Friend PJ1,
(1) Hepatobiliary Unit, Nuffield Department of Surgery;
(2) Department of Cellular Pathology, John Radcliffe Hospital,
Oxford, UK
EHPBA European Congress Abstracts 15
INTRODUCTION AND AIM: Malignant stromal tumors of the
duodenum are rare. We present a case of a metastatic duodenal
gastrointestinal stromal tumour (GIST) that was successfully treated
by simultaneous right hemihepatectomy and pancreaticoduode-
nectomy. PATIENTS AND METHODS: A 50-year-old woman
was admitted to our department for the treatment of a possible
metastatic duodenal GIST. At laparotomy a large duodenal tumor
was found displacing the head of the pancreas. A 3-cm diameter
lesion in the posterior aspect of segment VIII of the liver was also
noted. A simultaneous right hepatectomy and pancreaticoduode-
nectomy were performed. RESULTS: Histology revealed a high
grade metastatic duodenal GIST strongly positive for C-kit, CD34
and vimentin. The patient had no additional therapy. At a follow-up
of 22 months, the patient is very well and there is no evidence of
recurrent disease. CONCLUSION: Malignant stromal tumours of
the duodenum are usually slow growing, and the disease may be
amenable to curative surgery, even after metastases have occurred.
Resection of localised liver metastases is still advocated when feasi-
ble, as imatinib does not provide a complete or long-term response.
Combined hepatopancreatoduodenectomy is an efficacious treat-
ment for patients with metastatic duodenal GIST.
42 RIGHT PORTAL VEIN EMBOLIZATION BEFORE
RIGHT HEPATECTOMY FOR UNILOBAR COLORECTAL
LIVER METASTASES DOES NOT INCREASE THE
INCIDENCE OF INTRAHEPATIC RECURRENCE
Oussoultzoglou E, Jaeck D, Rosso E, Scurtu R, Bachellier P,
Weber JC, (1) Centre de Chirurgie Visce´rale et de Transplantation,
CHU Hautepierre, Strasbourg, France
INTRODUCTION AND AIM: It has been advocated that colo-
rectal liver metastases (CLM) could spread retrogradely via the
portal vein. Surgical maneuvers could contribute to local and
hematogenous dissemination of malignant tumors. No study has yet
been reported concerning the effect of preoperative right portal vein
embolization (PVE) on intrahepatic recurrence after CLM resection.
Our aim was to assess the impact of right PVE on the incidence of
recurrence after right hepatectomy for CLM. PATIENTS AND
METHODS: Between 1995 and 2003, 44 patients requiring a right
hepatectomy for unilobar CLM were operated in our institution. The
right hepatectomy was performed after preoperative right PVE in 23
patients (Group A) and without a PVE in 21 patients (Group B). We
compared the surgical outcome and site of recurrence in the two
groups. RESULTS: Patients characteristics were similar. The post-
operative mortality was nil. Overall morbidity and transitory liver
failure rates were also similar. The median follow-up was 24 months.
The 3- and 5-year overall survival rates were 61.2% and 43.7% in
Group A and 49.7% and 35.5% in Group B, respectively. There
were no significant differences between overall and disease-free
survival rates. Intrahepatic recurrences were significantly lower in
patients with PVE (26.0%) compared with those without PVE
(76.1%; p=0.0009) while recurrences at other sites were similar.
CONCLUSION: After right hepatectomy for unilobar CLM the
intrahepatic recurrence rate was significantly lower in patients with
preoperative right PVE. These results suggest that right PVE could
reduce intraoperative intrahepatic dissemination and recurrence.
43 SERUM ARGINASE ACTIVITY AND CLINICAL
STAGING OF COLORECTAL CANCER
Skwarek AM1, Nyckowski P1, Mielczarek M2, Chrzanowska A2,
Baranczyk-Kuzma A2, Krawczyk M1, Porembska Z2, (1) Department
of General, Transplant and Liver Surgery; (2) Department of
Biochemistry, Medical University, Warsaw, Poland
INTRODUCTION AND AIM: The authors present the analysis of
correlation between staging of colorectal cancer and arginase activity
in the serum of patients with colorectal adenocarcinoma.
PATIENTS AND METHODS: We analyzed a group of 149
patients:17 (11.4%) with primary colorectal adenocarcinoma; 117
(78.5%) with metachronous and 15 (10.1%) with synchronous liver
metastases. Controls were 137 normal healthy volunteers. Staging
was based on TNM classification. Arginase activity was measured by
Chinard’s method before and 6 days after the operation. RESULTS:
In all groups T1 tumors were not found. Mean serum arginase
activity was T2-46.9 U/L,T3-53.1 U/L,T4-173.9 U/L in group I;
T2-236.9 U/L,T3-127.5 U/L,T4-103.3 U/L in group II and
T2-98.9 U/L,T3-115.2 U/L,T4-129.0 U/L in group III. Taking
into account stage N these values were as follows: N0-21.3 U/L,
N1-69.6 U/L, N2-57.1 U/L, N3-291.0 U/L (group I); N0-116.6
U/L, N1-138.5 U/L, N2-157.2 U/L (group II) and N0-106.6 U/L,
N1-99.8 U/L, N2-172.13 U/L (group III). For group II and III we
evaluated the correlations between the presence of nodal metastases
in hepatic-duodenal ligament and arginase activity: N0-157.8 U/L,
N1-92.4 U/L and N0-91.2 U/L, N1-136.8 U/L, respectively.In all
groups at 6 days after the operation we found decreasing serum
arginase activity ( p50.01). CONCLUSION: We observed a
significant correlation between TNM staging and preoperative serum
arginase activity of patients with colorectal adenocarcinoma.
44 SELECTIVE INTERNAL RADIATION THERAPY (SIRT)
FOR COLORECTAL LIVER METASTASES—SINGLE-CENTRE
EXPERIENCE WITH 100 PATIENTS
Stubbs RS, Correia MM, Mitchell A, Wakefield Gastroenterology
Centre, Wellington, New Zealand
INTRODUCTION AND AIM: SIRT is a promising new treatment
for non-resectable liver tumours. 90Yttrium microspheres placed via
the hepatic artery achieve selective tumour uptake and irradiation.
This paper presents an experience of SIRT in 100 consecutive
patients with non-resectable colorectal liver metastases treated
between January 1997 and March 2003. PATIENTS AND
METHODS: A single dose of between 2.0 and 3.0 GBq of
90Yttrium microspheres was given and followed by regional
chemotherapy in 77 patients. Responses were assessed by serial CT
scans and CEA measurement. RESULTS: Median CEA, as a
percentage of pre-treatment level, at 3, 6 and 12 months was 18.1%,
38.5% and 67.6%. Nine temporary complete responses occurred
within a median of 9 months. Progressive liver disease was seen in
10.5% after 3 months and in 19.6% after 6 months. Morbidity
(mainly gastroduodenal ulceration) was seen in 8.1% of patients
treated via a port and 35.7% for femoral catheter. One treatment-
related death occurred from radiation hepatitis. Median survival
from diagnosis of liver metastases was 16.2 months (range 1.1–
101.6). Kaplan-Meier estimated survival+SE at 6, 12, 18, 24 and 30
months was 76%+4.3, 48%+5, 32%+4.7, 18%+3.8 and 9%+2.8.
The most significant variables affecting survival were extrahepatic
disease (HR 6,2 : 1) and lack of regional chemotherapy (HR 3 : 1).
CONCLUSION: SIRT is a valid therapeutic option for non-
resectable colorectal liver metastases. The use of a port is a safer
approach and permits the use of regional chemotherapy which adds
benefit to the treatment. The best results are expected in those with
liver-only disease.
45 INFLUENCE OF TWO DIFFERENT RESECTION
TECHNIQUES FOR LIVER METASTASES FROM
COLORECTAL CANCER ON HEMATOGENOUS TUMOR
CELL DISSEMINATION—A PROSPECTIVELY RANDOMIZED
MULTICENTER TRIAL
Koch M, Antolovic D, Kienle P, Schmidt J, Weitz J, Buechler MW,
Department of Surgery, University of Heidelberg, Heidelberg,
Germany
INTRODUCTION AND AIM: Surgical removal of colorectal liver
metastases remains the treatment of choice and is associated with a
favourable prognosis in a significant number of patients. However,
30–50% of resected patients develop extrahepatic tumor recurrence,
which is probably caused by intraoperative hematogenous tumor cell
dissemination due to mechanical tumor manipulation during resec-
tion. We have recently demonstrated that the significantly enhanced
intraoperative hematogenous tumor cell spread during resection of
colorectal liver metastases is associated with a worse prognosis.
Therefore, we hypothesize that intraoperative hematogenous tumor
cell dissemination could be reduced or prevented by using the
anterior approach technique with primary dissection of the
parenchyma and without mobilization of the liver compared to
patients with conventional liver resection. PATIENTS AND
METHODS: This is a prospectively randomized multicenter trial
comparing the influence of two different liver resection techniques
(conventional liver resection versus anterior approach) on hemato-
genous tumor cell dissemination. RESULTS: From the first 20
patients, 11 patients were randomized for conventional resection and
9 patients for anterior approach. The median operating time in the
conventional group was 3 hours and 4 hours in the anterior approach
group ( p=0.02). Median blood loss (800 ml versus 1100 ml),
median hospital stay (9.5 versus 10 days) and morbidity (3
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complications in each group) were not significantly different between
the two groups. CONCLUSION: The anterior approach technique
is a safe and feasible resection technique for colorectal liver metas-
tases. The long-term oncological results of this study will clarify the
role of the anterior approach technique in surgical treatment of liver
metastases from colorectal cancer.
46 SEGMENTECTOMY (SGX) IS THE ONCOLOGICAL
EQUIVALENT OF HEMI-HEPATECTOMY (H-HPX) FOR
SMALLVOLUMECOLORECTALLIVERMETASTASES (CLM)
Nesbitt C1, Poston GJ2, Glendenning J1, Byrne C2, Ghaneh P1,
(1) Surgery, University of Liverpool; (2) Surgery, University
Hospital Aintree, Liverpool, UK
INTRODUCTION AND AIM: HPX is the only potentially curative
treatment for CLM. As awareness of the benefits of HPX and
methods of CLM detection improve, smaller volume disease is being
increasingly diagnosed. Historically, most CLM patients underwent
H-HPX. Recently, the trend has been towards more local resections
of smaller volume disease, with increasing use of hepatic preserva-
tion. This trend raises questions of oncological benefit; whether this
approach increases the risk of residual disease in the ipsilateral liver
remnant? The aim of this study was to examine the site of liver-only
recurrence (LOR), with particular reference to ipsilateral-LOR after
unilateral-SGX. PATIENTS AND METHODS: A prospectively
collected single-centre data set was examined. 5-year follow-up data
were identified for 184 patients post-HPX for CLM. Data were
stratified for: survival; recurrence site (LOR, extrahepatic, both);
LOR ipsilateral, contralateral, bilateral. RESULTS: 72 disease-free
at 5 years post-HPX (39%), 42 LOR (23%), 32 extrahepatic (17%),
28 hepatic+extrahepatic. Comparing LOR site with resection type:
19 LOR following unilateral-SGX of which 7 were ipsilateral-LOR
(37%), 5 contralateral-LOR, 7 bilateral-LOR; 14 LOR after bilat-
eral-SGX; 28 LOR following H-HPX. CONCLUSION: 54/61 LOR
were either contralateral or bilateral following either SGX or H-
HPX, compared to 7/19 ipsilateral-LOR (37%) following unilateral-
SGX. These data would support a policy of a more conservative
approach (SGX over H-HPX) in the management of low-volume
unilateral CLM.
47 SURVIVAL AFTER SURGICAL RESECTION OF
HEPATIC METASTASES IN PATIENTS WITH EXPANDED
INDICATIONS. A SINGLE-CENTER EXPERIENCE
Figueras J1, Torras J1, Llado L1, Ramos E1, Serrano T2, Valls C3,
Losa L1, Montserrat A1, Rafecas A1, (1) Department of Surgery;
(2) Department of Pathology; (3) Department of Radiology,
Hospital Universitario de Bellvitge, Barcelona, Spain
INTRODUCTION AND AIM: Surgical resection of hepatic
metastases (HM) of colorectal cancer (CRC) is the only option for
long-term survival, but only 10–20% of patients have resectable
metastases. Accepted indications for resection are 54 HM, unilo-
bar, size 55 cm without extrahepatic disease. The aim was to
analyse long-term survival in expanded indications. PATIENTS
AND METHODS: From 1991 to 2003, 439 patients were operated
for HM of CRC. Neither the number nor the size of HM were
considered a contraindication. Mean number of HM per patients
was 2.4+2.1(1–21), 89 had 44 HM and 159 (30%) were bilobar.
Resectable extrahepatic disease was found in 159 (30%). 39 patients
underwent simultaneous resection of CRC and HM. In 38 patients a
re-hepatectomy was performed, 52 patients underwent radio-
frequency, while in 55 patients resection of pulmonary metastases
was also performed. RESULTS: Postoperative mortality was 3%. 1-,
3- and 5-year actuarial survival were 89%, 61% and 40%, respec-
tively. 5-year survival of patients with solitary, 2–3, 4–5, and45 HM
was 44%, 42%, 33% and 17%, respectively. In patients with bilobar
HM was 34%, for size 55 cm 39% and in patients with resectable
extrahepatic disease was 8%. 5-year survival for simultaneous surgery
was 38%, for re-hepatectomy was 23%, while survival after radio-
frecuency was 22%; survival of patients with resection of pulmonary
metastases was 46%. In the multivariate analysis: CEA levels
450 ng/ml, 4 or more metastases, synchronic, extrahepatic disease
and margin invasion were independent factors for mortality.
CONCLUSION: Resection of colorectal metastases with curative
intention in patients with expanded indications gives an excellent
long-term survival.
48 LIVER METASTASES RESECTION. A TECHNIQUE
THAT MAKES IT EASIER
de Santiban˜es E, Sa´nchez Claria´ R, Palavecino M,
Hepato-Pancreato-Biliary Surgery and Liver Transplantation,
Hospital Italiano, Buenos Aires, Argentina
INTRODUCTION AND AIM: Liver resection is the only ther-
apeutic option that achieves long-term survival for patients with
hepatic metastases from colorectal (CR), neuroendocrinal (NE) or
non-colorectal non-neuroendocrinal tumors (NCRNNE). We
propose a technique that causes traction and counter-traction on the
resection area, thus easily exposing the structures to be ligated. As
the parenchyma protrudes like a cork from a bottle we named
this procedure “corkscrew technique”. The aim of this study is to
describe an original surgical technique to resect liver metastases.
PATIENTS AND METHODS: We delimite the resection area at
2 cm from the tumor. We place separated stitches, in a radiate way.
The needle diameter must allow passing far from the deepest margin
of the tumor. The stitches must be tractioned all together to separate
the tumor from the normal parenchyma. This easily exposes vascular
and biliary structures, as the consequence of traction and counter-
traction. Between 1983 and 2003 we performed 705 hepatectomies
for CR metastases, 50 for NE metastases and 40 for NCRNNE
metastases. In 516 (65%) patients we only applied the corkscrew
technique and in the other 279 (35%) patients we carried out an
anatomical resection (sectionectomy, hepatectomy, etc.). In 70 of
279 patients we combined a wedge resection with the corkscrew
technique. RESULTS: Mortality was 1%. Morbidity was 16% with
a reoperation rate of 3%. Global survival at 5 years was 33%.
CONCLUSION: The corkscrew technique is simple and safe, it
spares surgical time, avoids blood loss, ensures free tumor margins
and is easy to perform.
49 RECURRENCE AND OUTCOME AFTER
PERCUTANEOUS RADIOFREQUENCY ABLATION VS
HEPATIC RESECTION FOR SYNCHRONOUS COLORECTAL
LIVER METASTASES
Schneider B1, Pitton M1, Thies J2, Herber S1, Otto G2,
(1) Radiology; (2) Transplantation Surgery, University Mainz,
Mainz, Germany
INTRODUCTION AND AIM: Surgery is the standard approach to
treat colorectal liver metastases.The aim of this retrospective study
was to compare surgery with radiofrequency ablation (RFA) in
synchronous metastases. PATIENTS AND METHODS: Depend-
ing on localization and size of the metastases, patients were treated by
RFA (n=23) or surgery (n=27). Number of lesions was 67 (median
3, range 1–7) and 87 (median 3, range 1–7), median diameters
30 mm (range 5–70 mm) and 40 mm (range 15–140 mm) in the
RFA group and surgical group respectively. Six patients initially
treated by RFA had subsequent surgery and 3 patients with initial
surgery subsequently had RFA. Median follow-up was 519 (RFA)
and 689 (surgery) days, respectively. Kaplan-Meier estimates have
been used to calculate survival and freedom from recurrence.
RESULTS: Five of 23 and 8 of 27 patients after RFA and surgery
remained tumor-free after a median interval of 100 and 256 days
( p=0.03), respectively. In 10 patients recurrence occurred at the site
of RFA (10 of 67 treated lesions), whereas the rate of local recurrence
was 8 of 27 after surgery. Additional liver metastases and systemic
disease occurred in 12 and 8 patients after RFA and in 18 and 12 after
surgery, respectively. Median survival was 775 days after surgery,
after RFA it has not been reached ( p=0.23). CONCLUSION: In
patients with synchronous hepatic metastases, surgery results in a
longer recurrence-free interval than RFA, whereas survival is
comparable. Due to local recurrence, there appears to be a comple-
mentery role of both approaches which may improve the chance for
cure.
50 IN-CONTIGUITY (IC) AND NON-ANATOMICAL (NA)
EXTENSION OF RIGHT HEPATIC TRISECTIONECTOMY
FOR LIVER METASTASES
Menon KV, Fenwick SW, Prasad RK, Lodge PA, Department of
Hepatobiliary Surgery, St James’s University Hospital, Leeds, UK
INTRODUCTION AND AIM: In some patients undergoing a right
trisectionectomy for metastases if tumour is encroaching onto
segments 2, 3 or both, extension of the resection beyond the falciform
ligament is necessary to achieve tumour clearance. The aim of the
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present study was to assess the early and long-term outcomes and
hepatic function in a cohort of patients who underwent extensive liver
resections beyond a right trisectionectomy. PATIENTS AND
METHODS: All patients who underwent extension of a right
trisectionectomy either in-contiguity (IC) or in a non-anatomical
fashion (NA) for liver metastases from January 1993 to December
2001 were included in the study. In-hospital mortality, hepatic
function and other morbidity were recorded. Survival outcomes were
analysed for the subgroup of patients with colorectal liver metastases.
Clinical risk score described by the Memorial Sloan-Kettering
Cancer Center (MSKCC) group was applied to all patients with
colorectal liver metastases. RESULTS: 38 patients underwent an
extension of a right trisectionectomy for metastases.16 patients
underwent IC resections, 15 had a non-anatomical resection and 7
had both IC and NA resections. We had one in-hospital death
(2.7%). Hepatic dysfunction was seen in 25 (66%) patients and 2
(5%) developed liver failure. Disease-free survival was 42% for
colorectal liver metastases. Survival was significantly better for
patients with clinical risk score of 53 (Log rank test, p=0.01).
CONCLUSION: Extension of a right trisectionectomy (IC and NA)
for liver metastases can be safely performed with low mortality and
hepatic failure is uncommon. In patients with colorectal liver
metastases survival was significantly better for patients with a clinical
risk score of53.
51 DEVELOPMENT AND CLINICAL APPLICATION OF
COMPUTER-AIDED 3-D PLANNINGSYSTEMFORTHERMAL
ABLATION OF HEPATIC TUMORS
Ritz JP1, Lehmann K1, Valdeig S1, Frericks B2, Peitgen H3, Buhr H1,
(1) Department of Surgery I, Charite Campus Benjamin Franklin;
(2) Department of Radiology, Charite Campus Benjamin Franklin,
Berlin, Germany; (3) Mevis GmbH Bremen, Bremen, Germany
INTRODUCTION AND AIM: Thermal ablation procedures like
laser-induced thermotherapy (LITT) or radiofrequency therapy are
being increasing applied in the treatment of nonresectable liver
tumors. A major drawback of these procedures is the inability to
predict the emerging thermal lesions with the risk of local recurrence.
The aim of this study was to test our 3-D planning system under
clinical conditions both experimentally and in patients with liver
metastases. PATIENTS AND METHODS: A tissue data bank of
optical tissue parameters (human/animal/healthy/tumor, n=120
samples) was used as a basis. The parameters of the planned LITT
(length of application, application energy, perfusion) are entered into
the computer-aided irradiation model, creating a 3-D image of
simulated coagulation size. These simulations (LongSim, TransSim,
VolSim) were correlated to the actual lesion volume in 15 domestic
pigs. The animals were randomized into three groups: normal hepatic
profusion (LITTmono); interrupted perfusion by the Pringle
maneuver (LITTPringle); microembolization with starch micro-
spheres (LITTDSM). Moreover, the simulation results were
compared to the post-interventional MRI data of 5 patients with
nonresectable liver metastases (LITTPat), who were treated by
percutaneous LITT (Nd:YAG laser, 28 W, 20 min). After the
intervention, the lesions were longitudinally (LongLITT) and
transversally (TransLITT) measured (macroscopically or Gd-DTPA
MRI) and the volumes calculated. RESULTS: Simulating coagula-
tion size takes 28.5 (23–37) minutes. By interrupting perfusion,
simulated and in vivo lesion volumes increased by 4.5-fold (DSM)
and 10-fold (Pringle). The deviation of the simulated diameter
from the in vivo data in the animal experiments was a maximal
3.1%+0.3 (LITTmono), 2.6%+0.3 (LITTPringle) and
15.6%+3.7 (LITTDSM), corresponding to 0.2 cm, 0.3 cm and
0.7 cm. The patient data differed by 8.5% (long.), 9.1% (transv.)
and 11.2% (volumes), corresponding to a maximum of 0.9 cm.
CONCLUSION: (1) The 3-D irradiation model experimentally
showed very good agreement between simulated and in vivo data with
prediction of coagulation size in LITT under normal and completely
interrupted hepatic perfusion. (2) Clinical application of the plan-
ning program for liver metastases demonstrated greater deviations of
about 1 cm and must be calculated into LITT planning. (3) Due to
the tri-dimensional construction of the model, it was possible to make
a statement for the first time about the expected lesion geometry and
the required application parameters for safe tumor volume destruc-
tion in interstitial in situ ablation techniques.
52 THE IMPACT OF NEO-ADJUVANT TREATMENT ON
THE ACCURACY OF FDG PET-CT IN PATIENTS WITH
COLORECTAL METATASES TO THE LIVER: COMPARISON
WITH OPERATIVE AND PATHOLOGICAL FINDINGS
Ben-Haim M1, Nakache R1, Even-Sapir E2, Figer A2, Klausner J1,
Lubezky N1, (1) Surgery B and Transplantation; (2) Nuclear
Medicine; (3) Oncology, Tel-Aviv Sourasky Medical Center,
Tel-Aviv, Israel
INTRODUCTION AND AIM: FDG-PET and neoadjuvant
chemotherapy before hepatic resection may improve the therapeutic
management of patients with colorectal liver metastases. We meant
to assess the impact of neoadjuvant chemotherapy on the accuracy of
FDG-PET. PATIENTS AND METHODS: Patients were assigned
to either neoadjuvant treatment or immediate hepatic resection
according to the resectability and the risk of reccurence (MSKCC
clinical score42). Neoadjuvant regimens were based on Irinotecan
or Oxaliplatin. All were evaluated with CT and FDG-PET before
treatment and before surgery. Surgery included intra-operative
ultrasound (IOUS) and resection of all metastatic sites. Operative
and pathological findings were compared to the CT and FDG-PET.
RESULTS: 51 patients were studied. 24 patients, with 24 liver
lesions, underwent immediate hepatic resection (group 1), and 27
patients, with 54 lesions, were operated following neoadjuvant
chemotherapy (group 2). For group 1, FDG-PET was true positive
(TP) in 20 lesions, false negative (FN) in 3 lesions and false positive
(FP) in 1 case. Sensitivity was 87% and accuracy 83%. For group 2,
FDG-PET was TP in 23 lesions, true negative (TN=complete
FDG-PET and complete pathological response) in 18 lesions. It was
FP in 3 lesions, and FN in 12 lesions (FN=complete FDG-PET
response but not complete pathological response). The sensitivity,
specificity and accuracy were therefore 66%, 86% and 73%,
respectively, significantly inferior to the results in group 1 ( p=0.03).
CONCLUSION: Sensitivity of FDG-PET decreases significantly
following neoadjuvant chemotherapy. In this setting, the justification
and extent of resection should be guided by additional imaging tools
(CT and IOUS) and by the original imaging.
53 LIVER SURGERY FOR INITIALLY NON-RESECTABLE
LIVER METASTASES DOWNSTAGED BY CHEMOTHERAPY:
SHORT- AND LONG- TERM RESULTS COMPARED TO
PATIENTS UNDERGOING IMMEDIATE RESECTION
Muratore A, Sgotto E, Bouzari H, Ribero D, Capussotti L,
Surgical Oncology, Instituto per la Ricerca e la Cura del Cancro,
Candiolo (To), Italy
INTRODUCTION AND AIM: Oxaliplatin-based chemotherapy
downstages up to one-third of patients with non-resectable colorectal
cancer liver metastases. Short- and long-term results of the patients
undergoing resection after neoadjuvant chemotherapy are compared
to patients treated by primary liver resection. PATIENTS AND
METHODS: From January 2000 to June 2004, 35 initially unre-
sectable (group A) patients underwent hepatic resection after oxali-
platin-based chemotherapy, whereas 117 resectable cases (group B)
had immediate liver surgery. RESULTS: A major hepatic resection
was performed in 21 (60%) cases of group A and in 46 cases (39.3%)
of group B ( p=0.03). Both groups had a similar rate of radical
operations. In-hospital mortality was 0%. Postoperative morbidity
was 37.1% in group A and 23.9% in group B ( p=0.1); two patients
developed postoperative liver failure, both in group B. Overall and
survival at 3 years was 69.9% in group A and 69.7% in B ( p=0.5);
median and 3-year disease-free survival were 9 months and 31.6% in
A and 38 months and 52.7% in B ( p=0.005). Twenty-eight patients
(80%) of group A had a recurrence (re-resection in 35.7% of the
cases) versus 63 (53.8%) of group B (re-resection in 42.8% of the
cases) ( p=0.005). By the end of follow-up, 11 patients (31.4%) of
group A and 62 patients (52.9%) of group B were alive and without
disease. CONCLUSION: Long-term survival of patients resectable
after neoadjuvant chemotherapy is similar to that of patients under-
going liver surgery d’amble`. However, disease-free survival is
significantly shorter.
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